CORONAVIRUS PROTEINS AND ANTIGENS
Publication number: 20160339097
Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
Type: Application
Filed: August 4, 2016
Publication date: November 24, 2016
Applicant: MJ Biologics, Inc.
Inventor: Byoung-Kwan Kim

CORONAVIRUS PROTEINS AND ANTIGENS
Publication number: 20190202868
Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
Type: Application
Filed: March 15, 2019
Publication date: July 4, 2019
Applicant: Phibro Animal Health Corporation
Inventor: Byoung-Kwan Kim

Coronavirus proteins and antigens
Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
Type: Grant
Filed: August 4, 2016
Date of Patent: May 7, 2019
Assignee: Phibro Animal Health Corporation
Inventor: Byoung-Kwan Kim

Vaccine compositions and methods of treating coronavirus infection
Publication number: 20060286124
Abstract: The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus.
Type: Application
Filed: June 30, 2005
Publication date: December 21, 2006
Applicant: ID Biomedical Corporation of Quebec
Inventor: David Burt, Mark Reddish, Mary Hu, George Lowell, David Jones

Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
Publication number: 20050276818
Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
Type: Application
Filed: May 17, 2005
Publication date: December 15, 2005
Inventor: Adam Godzik, Sergey Sikora

Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
Type: Grant
Filed: May 17, 2005
Date of Patent: March 17, 2009
Assignee: The Burnham Institute
Inventor: Adam Godzik, Sergey Sikora

Inactivated canine coronavirus vaccine
Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed.
Type: Grant
Filed: June 7, 1984
Date of Patent: January 28, 1986
Assignee: American Home Products Corporation
Inventor: William M. Acree, Bobby Edwards, John W. Black

CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLUTININ/ESTERASE
Publication number: 20090081780
Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.
Type: Application
Filed: September 26, 2008
Publication date: March 26, 2009
Applicant: The Royal Veterinary College
Inventor: John Brownlie, Victoria Jane Chalker, Kerstin Erles

PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
Publication number: 20200061185
Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
Type: Application
Filed: October 25, 2017
Publication date: February 27, 2020
Inventor: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett

PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION THEREOF
Publication number: 20100304363
Abstract: Disclosed herein are peptide compounds and the application thereof to the detection and inhibition of SARS coronavirus. Composed of dipeptides, the compounds for detecting and inhibiting SARS coronavirus can be readily synthesized and produced at low cost. In addition, they can be stored safely for a long period of time. The dipeptide compounds are useful as inhibitors of SARS coronavirus as well as acting as excellent capturing materials of SARS coronavirus.
Type: Application
Filed: May 26, 2010
Publication date: December 2, 2010
Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
Inventor: Soo-Hyung LEE, Hyo-Bong Hong, Tao-Wan Kim, Myung-Ae Chung, Sung-Woo Sohn, Seoung-Min Yoo

Canine respiratory coronavirus (CRCV) spike protein
Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.
Type: Grant
Filed: September 26, 2008
Date of Patent: July 19, 2011
Assignee: The Royal Veterinary College
Inventor: John Brownlie, Victoria Jane Chalker, Kerstin Erles

Canine Respiratory Coronavirus (Crcv) Spike Protein, Polymerase and Hemagglutinin/Esterase
Publication number: 20070248616
Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
Type: Application
Filed: July 1, 2003
Publication date: October 25, 2007
Inventor: John Brownlie, Victoria Chalker, Kerstin Erles

Methods and compositions for infectious cDNA of SARS coronavirus
Publication number: 20060240530
Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.
Type: Application
Filed: January 19, 2006
Publication date: October 26, 2006
Inventor: Ralph Baric, Rhonda Roberts, Boyd Yount, Kristopher Curtis

Compositions and methods for detecting severe acute respiratory syndrome coronavirus
Publication number: 20050095582
Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
Type: Application
Filed: November 3, 2003
Publication date: May 5, 2005
Inventor: Laura Gillim-Ross, Jill Taylor, David Scholl, David Wentworth, Joseph Jollick

Compositions and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus
Publication number: 20080076115
Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
Type: Application
Filed: November 3, 2004
Publication date: March 27, 2008
Inventor: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth

Ribozyme to cleave coronavirus gene
Publication number: 20100273997
Abstract: Provided is a ribozyme to cleave a coronavirus gene and a therapeutic agent for a coronavirus infectious disease. A common base sequence in coronaviruses such as SARS-CoV and MHV was searched to design a ribozyme including a base sequence complementary thereto. Moreover, a therapeutic agent for a coronavirus infectious disease including such ribozyme was obtained.
Type: Application
Filed: August 9, 2006
Publication date: October 28, 2010
Inventor: Noboru Fukuda, Takahiro Ueno, Akiko Fukushima, Kazumichi Kuroda

Compositions And Methods For Detecting Severe Acute Respiratory Syndrome Coronavirus
Publication number: 20110223659
Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
Type: Application
Filed: December 7, 2010
Publication date: September 15, 2011
Inventor: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth

Compositions and methods for treating coronavirus infection and SARS
Publication number: 20050002901
Abstract: The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection.
Type: Application
Filed: March 30, 2004
Publication date: January 6, 2005
Inventor: Lawrence Blatt

FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES
Publication number: 20100150923
Abstract: Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimized SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided.
Type: Application
Filed: June 13, 2006
Publication date: June 17, 2010
Applicant: Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences
Inventor: Chengyu Jiang, Feng Guo, Shuan Rao, Bing Guan, Yi Huan, Peng Yang

Civet animal model system for Severe Acute Respiratory Syndrome (SARS) coronavirus infection and uses thereof
Publication number: 20060123499
Abstract: The present invention is directed towards the use of the masked palm civet Paguma larvata (“civet”) as an animal model system for SARS, and is based on the novel demonstration of the present invention that civets may be infected with exogenous coronavirus, and that such infection produces SARS-like symptoms in these infected animals. The present invention is directed to a civet model system for the study of the infection, replication, and clinical effects of exogenously introduced human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof, and to the development of vaccines (or other methods of prevention) or treatment of infection or transmission to other civets or humans of these human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof.
Type: Application
Filed: December 6, 2004
Publication date: June 8, 2006
Inventor: Donglai Wu, Xiangang Kong, Qingwen Meng, Yonggang Liu, Yuntao Guan, Xunnan Yin, Mouping Wang, Changwen Li, Ming Liao, Chao-an Xin, Jinding Chen, Changchun Tu, Hua Xuan, Yedong Yu

Glycyrrhizin or derivatives thereof for for treating or preventing severe acute respiratory syndrome (sars)
Publication number: 20070099855
Abstract: The invention provides methods for preventing, treating, managing or ameliorating viral infections, in particular, Severe Acute Respiratory Syndrome (SARS). More specifically, the invention provides methods for preventing, treating, managing or ameliorating a SARS-associated coronavirus or one or more symptoms thereof by administering Glycyrrhizin and/or derivatives thereof The invention also provides methods for preventing, treating, managing or ameliorating a SARS-associated coronavirus or one or more symptoms thereof by administering Glycyrrhizin and/or a derivative thereof in combination with a prophylactic or therapeutic agent other than Glycyrrhizin or a derivative thereof.
Type: Application
Filed: June 7, 2004
Publication date: May 3, 2007
Applicant: Johann Wolfgang Goethe University
Inventor: Jindrich Cinatl

Viral protein
Abstract: The present invention is directed to an isolated polypeptide containing SEQ ID NO: 1 or an immunogenic fragment thereof. Also disclosed is an isolated nucleic acid encoding the polypeptide or containing a sequence at least 70% identical to SEQ ID NO: 3. Within the scope of this invention are related expression vectors, host cells, and antibodies. Also disclosed are methods of producing the polypeptide, diagnosing coronavirus infection, and identifying a test compound for treating coronavirus infection.
Type: Grant
Filed: September 19, 2007
Date of Patent: April 6, 2010
Inventor: Fang-Jen Lee, Chia-Jung Yu, Ming-Fu Chang, Hong-Nerng Ho

Preventive or therapeutic composition for viral infectious disease
Abstract: The invention provides a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing one or more substances selected from reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin, and a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin.
Type: Grant
Filed: July 22, 2004
Date of Patent: February 19, 2008
Assignee: Kyowa Hakko Kogyo Co., Ltd.
Inventor: Satoru Furukawa, Hideo Kawabe, Hitoshi Ohori, Takao Mukai, Mitsuyo Matsumoto

Corona-virus-like particles comprising functionally deleted genomes
Publication number: 20050186575
Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines therefor. Methods are shown for at least in part inhibiting anti-parallel coiled coil formation of a coronavirus spike protein which methods include decreasing the contact between heptad repeat regions of the coronavirus spike protein. The invention provides a peptide comprising a heptad repeat region of a coronaviral spike protein and/or a functional fragment and/or a derivative thereof. The invention also provides antibodies and compounds inhibiting coronaviral infection of cells, and/or cell-to-cell fusion. The invention also includes heptad repeat regions and a fusion peptide of SARS-CoV.
Type: Application
Filed: December 30, 2003
Publication date: August 25, 2005
Inventor: Petrus Rottier, Berend Bosch

Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
Publication number: 20050187192
Abstract: Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.
Type: Application
Filed: February 20, 2004
Publication date: August 25, 2005
Inventor: Ronald Fleming, Jan Hes, Yunsheng Huang, Russ Read, Susan Morris-Natschke, Khalid Ishaq, Louis Kucera, Phillip Furman

INFECTIOUS CLONES
Publication number: 20110142879
Abstract: Methods of preparing a DNA comprising sequences derived from the genomic RNA (gRNA) of a coronavirus are provided, comprising cloning under the expression of a promoter a coronavirus interfering defective genome into a bacterial artificial chromosome (BAC) and reinserting into said genome the deleted sequences within the defective genome, wherein said sequences have a homology of at least 60% to the natural sequence of the virus, wherein said sequences code for an RNA-dependent RNA polymerase and at least one structural or non-structural protein, and wherein a fragment of said DNA is capable of being transcribed into RNA and assembeld to a virion. Also provided are infective clones, recombinant viral vectors, and vaccines.
Type: Application
Filed: November 3, 2010
Publication date: June 16, 2011
Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Inventor: LUIS ENJUANES SANCHEZ

Methods for treating respiratory viral infection
Abstract: Provided herein are methods for modulating immune responses to a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof. Also provided herein are methods for treating, preventing, ameliorating, and/or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.
Type: Grant
Filed: April 5, 2011
Date of Patent: August 9, 2016
Assignee: Celgene Corporation
Inventor: Jerome B. Zeldis

METHODS FOR TREATING RESPIRATORY VIRAL INFECTION
Publication number: 20130136770
Abstract: Provided herein are methods for modulating immune responses to a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof. Also provided herein are methods for treating, preventing, ameliorating, and/or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.
Type: Application
Filed: April 5, 2011
Publication date: May 30, 2013
Applicant: CELGENE CORPORATION
Inventor: Jerome B. Zeldis

Inactivated bovine scours vaccines, processes and method of preventing bovine scours
Publication number: 20020155128
Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.
Type: Application
Filed: February 4, 2001
Publication date: October 24, 2002
Inventor: Kelly Knape, Stephanie Dykstra, Mary Tinant

Inactivated bovine scours vaccines, process and method of preventing bovine scours
Publication number: 20050281842
Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.
Type: Application
Filed: August 1, 2005
Publication date: December 22, 2005
Inventor: Kelly Knape, Stephanie Dykstra, Mary Tinant

Phospholipids for the Treatment of Infection by Togaviruses, Herpes Viruses and Coronaviruses
Publication number: 20100273740
Abstract: Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.
Type: Application
Filed: November 23, 2009
Publication date: October 28, 2010
Inventor: Ronald A. FLEMING, Jan V. Hes, Yunsheng Huang, Russ H. Read, Susan L. Morris-Natschke, Khalid S. Ishaq, Louis S. Kucera, Phillip A. Furman

MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES
Publication number: 20150133368
Abstract: Antiviral protease inhibitors, including macrocylic transition state inhibitors and peptidomimetics are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, sapoviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.
Type: Application
Filed: May 2, 2013
Publication date: May 14, 2015
Inventor: Kyeong-Ok Chang, Yunjeong Kim, William C. Groutas

BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUS-LIKE SUPERCLUSTER: PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES
Publication number: 20140243341
Abstract: Antiviral protease inhibitors, including peptidyl aldehydes, peptidyl ?-ketoamides, peptidyl bisulfite salts, and peptidyl heterocycles, are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.
Type: Application
Filed: September 27, 2012
Publication date: August 28, 2014
Inventor: Kyeong-Ok Chang, Yunjeong Kim, William C. Groutas, Duy Hua, Linda J. Saif

Novel human virus causing respiratory tract infection and uses thereof
Publication number: 20060018923
Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen, China. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.
Type: Application
Filed: July 21, 2004
Publication date: January 26, 2006
Inventor: Kwok Yuen, Chiu Woo, Kar Lau, Kwok Chan, Lit Poon, Joseph Peiris, Yi Guan

Inactivated bovine scours vaccines, processes and method of preventing bovine scours
Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.
Type: Grant
Filed: February 4, 2001
Date of Patent: December 13, 2005
Assignee: Novartris AG
Inventor: Kelly Knape, Stephanie Dykstra, Mary Tinant

Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses
Abstract: Antiviral protease inhibitors, including macrocylic transition state inhibitors and peptidomimetics are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, sapoviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.
Type: Grant
Filed: May 2, 2013
Date of Patent: April 12, 2016
Inventor: Kyeong-Ok Chang, Yunjeong Kim, William C. Groutas

Potent and Selective Inhibition by Aurinticarboxylic Acid
Publication number: 20110112195
Abstract: The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine development takes years to complete and adverse reactions have been reported to some veterinary coronaviral vaccines, anti-viral compounds must be relentlessly pursued. In this study, we analyzed the effect of aurintricarboxylic acid (ATA) on SARS-CoV replication in cell culture, and found that ATA could drastically inhibit SARS-CoV replication, with viral production being more than 1000 fold than that in the untreated control. ATA is also shown to be an effective anti-viral for several other viruses, including West Nile Virus and variola virus.
Type: Application
Filed: June 15, 2005
Publication date: May 12, 2011
Inventor: Runtao He, Anton Andonov, Jingxin Cao, Mike Drebot, Xueguang Li

Inactivated bovine scours vaccines, process and method of preventing bovine scours
Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.
Type: Grant
Filed: August 1, 2005
Date of Patent: December 18, 2007
Assignee: Novartis AG
Inventor: Kelly Knape, Stephanie Dykstra, Mary Tinant

NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF
Publication number: 20090305282
Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen. China. The virus belongs to the order Nidovirales of the family Coronavirdae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.
Type: Application
Filed: June 1, 2009
Publication date: December 10, 2009
Inventor: KWOK YUNG YUEN, CHIU YAT PATRICK WOO, KAR PUI SUSANNA LAU, KWOK HUNG CHAN, LIT MAN POON, JOSEPH SRIYAL MALIK PEIRIS, YI GUAN

Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
Abstract: Antiviral protease inhibitors, including peptidyl aldehydes, peptidyl ?-ketoamides, peptidyl bisulfate salts, and peptidyl heterocycles, are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.
Type: Grant
Filed: September 27, 2012
Date of Patent: October 25, 2016
Inventor: Kyeong-Ok Chang, Yunjeong Kim, William C. Groutas, Duy Hua, Linda J. Saif

Novel human virus causing respiratory tract infection and uses thereof
Publication number: 20060034853
Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as human coronavirus-HKU1 (“HCoV-HKU1”), isolated in Hong Kong. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. Futher study on nasopharyngeal aspirates from patients with community-acquired pnbeumonia has revealed that there are two genotypes, genotype A and genotype B, for this virus. In addition to the genomic sequences of these two genotypes, the invention provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the HCoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by HCoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the HCoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the HCoV-HKU1.
Type: Application
Filed: May 16, 2005
Publication date: February 16, 2006
Inventor: Kwok Yuen, Chiu Yat Woo, Kar Pui Lau, Kwok Chan

Imageable animal model of SARS infection
Publication number: 20050039220
Abstract: Imaged animal models for coronavirus infection are described.
Type: Application
Filed: May 27, 2004
Publication date: February 17, 2005
Inventor: Meng Yang, Mingxu Xu

Human virus causing respiratory tract infection and uses thereof
Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen, China. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.
Type: Grant
Filed: July 21, 2004
Date of Patent: June 30, 2009
Assignee: The University of Hong Kong
Inventor: Kwok Yung Yuen, Chiu Yat Patrick Woo, Kar Pui Susanna Lau, Kwok Hung Chan, Lit Man Poon, Joseph Sriyal Malik Peiris, Yi Guan

Human virus causing respiratory tract infection and uses thereof
Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen, China. The virus belongs to the order Nidovirales of the family Coronavirdae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.
Type: Grant
Filed: June 1, 2009
Date of Patent: January 10, 2012
Assignee: Versitech Limited
Inventor: Kwok Yung Yuen, Chiu Yat Patrick Woo, Kar Pui Susanna Lau, Kwok Hung Chan, Lit Man Poon, Joseph Sriyal Malik Peiris, Yi Guan

Human virus causing respiratory tract infection and uses thereof
Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as human coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. Further study on nasopharyngeal aspirates from patients with community-acquired pneumonia has revealed that there are two genotypes, genotype A and genotype B, for this virus. In addition to the genomic sequences of these two genotypes, the invention provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.
Type: Grant
Filed: May 16, 2005
Date of Patent: May 13, 2008
Assignee: The University of Hong Kong
Inventor: Kwok Yung Yuen, Chiu Yat Patrick Woo, Kar Pui Susanna Lau, Kwok Hung Chan

PHENANTHROINDOLIZIDINE ANALOGUES
Publication number: 20100216773
Abstract: Treatment of coronavirus infection with phenanthroindolizidine analogues.
Type: Application
Filed: February 11, 2010
Publication date: August 26, 2010
Applicant: National Health Research Institutes
Inventor: Shiow-Ju Lee, Cheng-Wei Yang, Yue-Zhi Lee

Expression vector encoding coronavirus-like particle
Publication number: 20050282279
Abstract: The present invention relates to a expression vector for cloning the Class I viral fusion protein gene and as DNA vaccine candidate against virus infection diseases.
Type: Application
Filed: May 28, 2004
Publication date: December 22, 2005
Inventor: Paul Hwu

Treatment or prevention of respiratory viral infections with alpha thymosin peptides
Publication number: 20070036744
Abstract: An alpha thymosin peptide is administered to a patient having, or at risk of a respiratory viral infection, coronavirus infection and/or SARS.
Type: Application
Filed: April 23, 2004
Publication date: February 15, 2007
Applicant: SciClone Pharmaceuticals, Inc.
Inventor: Alfred Rudolph, Cynthia Tuthill

Phenanthroindolizidine analogues
Abstract: Treatment of coronavirus infection with phenanthroindolizidine analogues.
Type: Grant
Filed: February 11, 2010
Date of Patent: May 14, 2013
Assignee: National Health Research Institutes
Inventor: Shiow-Ju Lee, Cheng-Wei Yang, Yue-Zhi Lee

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
Publication number: 20170158752
Abstract: The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.
Type: Application
Filed: April 27, 2015
Publication date: June 8, 2017
Inventor: Wayne A. MARASCO, Xiangchun TANG

TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS WITH ALPHA THYMOSIN PEPTIDES
Publication number: 20100311656
Abstract: An alpha thymosin peptide is administered to a patient having, or at risk of a respiratory viral infection, coronavirus infection and/or SARS.
Type: Application
Filed: June 16, 2010
Publication date: December 9, 2010
Applicant: SciClone Pharmaceuticals, Inc.
Inventor: Alfred R. RUDOLPH, Cynthia W. TUTHILL

METHODS FOR DETERMINING THE PRESENCE OF SARS CORONAVIRUS IN A SAMPLE
Publication number: 20100279276
Abstract: Methods for determining the presence of SARS-CoV in a test sample that include targeting the SARS-CoV 5? leader sequence or the SARS-CoV 3? terminal sequence.
Type: Application
Filed: July 6, 2010
Publication date: November 4, 2010
Applicant: GEN-PROBE INCORPORATED
Inventor: Daniel L. KACIAN

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
Publication number: 20190194299
Abstract: The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.
Type: Application
Filed: November 19, 2018
Publication date: June 27, 2019
Inventor: Wayne A. Marasco, Xianchun Tang

Inhibition of sars coronavirus infection with clinically approved antiviral drugs
Publication number: 20060153803
Abstract: The invention relates to methods for treating or inhibiting SARS-CoV infection involving the administration of an interferon, particularly IFN ?-n1, IFN ?-n3, human leukocyte IFN ? or IFN ?-1b.
Type: Application
Filed: June 9, 2004
Publication date: July 13, 2006
Inventor: Emily Tan, Lawrence Stanton

USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONS
Publication number: 20190336456
Abstract: The use of xibornol as a virucidal agent is described in the prophylactic or therapeutic treatment of an infection caused by one or more viruses, said viruses comprising at least one of human Adenovirus, human Rhinovirus, human Coronavirus, and a combination thereof.
Type: Application
Filed: July 13, 2017
Publication date: November 7, 2019
Applicant: ABIOGEN PHARMA S.P.A.
Inventor: Cristina Bigini

MERS-CoV Vaccine
Publication number: 20170258893
Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
Type: Application
Filed: November 26, 2014
Publication date: September 14, 2017
Inventor: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai

Extracts of Scutellaria for the Treatment of Sars
Publication number: 20080038382
Abstract: The present invention relates to pharmaceutical compositions having antiviral activity against Coronavirus, and more particularly against those viruses responsible for Severe Acute Respiratory Syndrome (SARS). In a preferred embodiment it comprises a total standardized extract of a Scutellariae spp.
Type: Application
Filed: February 25, 2005
Publication date: February 14, 2008
Inventor: Shouming Zhong, Hongwen Yu, Robert Miller

Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
Abstract: The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.
Type: Grant
Filed: April 27, 2015
Date of Patent: November 20, 2018
Assignee: DANA-FARBER CANCER INSTITUTE, INC.
Inventor: Wayne A. Marasco, Xiangchun Tang

MERS-CoV Vaccine
Publication number: 20190022213
Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
Type: Application
Filed: June 29, 2018
Publication date: January 24, 2019
Inventor: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai

Live Attenuated Nidovirus Vaccines
Publication number: 20070286872
Abstract: The present invention is directed live, attenuated Nidovirus vaccines, and in a particular embodiment, to coronavirus vaccines. The vaccine comprises a viral genome encoding a replicase polyprotein having at least one proteinase cleavage site that exhibits reduced or no cleavage. Such viruses show reduced.
Type: Application
Filed: April 22, 2004
Publication date: December 13, 2007
Applicant: Vanderbilt University
Inventor: Mark Denison

VACCINE
Publication number: 20120045469
Abstract: The present invention provides an immunogenic composition comprising: an immunogenic SARS coronavirus S (spike) polypeptide, or a fragment or variant thereof; and an adjuvant comprising an oil-in-water emulsion.
Type: Application
Filed: December 1, 2009
Publication date: February 23, 2012
Applicant: GlaxoSmithKline Biologicals S.A.
Inventor: Benoit Baras, Benoit Callendret, Nicolas Escriou, Valerie Lorin, Philippe Marianneau, Sylvie Van Der Werf, Martine Anne Cecile Wettendorff

Antiviral Compositions and Methods
Publication number: 20070149487
Abstract: Compositions and methods for treating, preventing, or ameliorating one or more symptoms, conditions, or disorders associated with coronavirus infections are provided, in particular small-molecule inhibitors of the chymotrypsin-like cysteine protease of SARS CoV.
Type: Application
Filed: November 7, 2006
Publication date: June 28, 2007
Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Inventor: Yuan-Ping Pang, Andrea Dooley, Jewn Park

Use of golden hamster as infectivity model of SARS
Publication number: 20060143719
Abstract: A model system for sudden acute respiratory syndrome infection (SARS) in humans, comprising a non-human animal infected with a SARS-causing coronavirus (CoV), wherein the non-human animal is a golden hamster.
Type: Application
Filed: August 16, 2005
Publication date: June 29, 2006
Inventor: Philippe Marianneau, Vincent Deubel, Hugues Contamin, Ingrid Marendat, Philippe Loth, Marie Georges-Courbot

VACCINE
Publication number: 20100233250
Abstract: The present invention provides a vaccine or immunogenic composition comprising: an immunogenic SARS coronavirus S (spike) polypeptide, or a fragment or variant thereof; and an adjuvant comprising a lipopolysaccharide, a saponin and a liposome.
Type: Application
Filed: June 20, 2008
Publication date: September 16, 2010
Inventor: Benoit Baras, Benoit Callendret, Nicolas Escriou, Valerie Lorin, Philippe Marianneau, Sylvie Van Der Werf, Martine Anne Cecile Wettendorff

Use of a plastic composition and a product obtained thereby
Publication number: 20070082971
Abstract: Use of a plastic composition comprising an effective amount of an inorganic derivative containing silver, including silver salts and silver containing complexes for preparation of molded products respectively lacquered or painted products to provide them with a surface having antivirus activity even against SARS coronavirus and a product obtained thereby.
Type: Application
Filed: January 27, 2005
Publication date: April 12, 2007
Applicant: POLYGIENE AB
Inventor: Luigi Mocchia

Screening assay for inhibitors of severe acute respiratory syndrome (SARS) using SELDI-TOF Mass Spectrometry
Publication number: 20060257861
Abstract: Mass spectrometric methods directed to screening libraries of compounds for agents that inhibit entry of Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV) into cells are provided, along with methods for comparatively evaluating inhibitors of the SARS CoV.
Type: Application
Filed: May 12, 2006
Publication date: November 16, 2006
Applicant: Wright State University
Inventor: Khalid Elased, Mariana Morris

ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS LINKED TO CORONAVIRUSES
Publication number: 20190307722
Abstract: The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.
Type: Application
Filed: October 20, 2017
Publication date: October 10, 2019
Inventor: Manuel ROSA-CALATRAVA, Olivier TERRIER, Anaïs PROUST, Vincent MOULES

Canine coronavirus S gene and uses therefor
Abstract: The present invention provides the amino acid and nucleotide sequences of a CCV spike gene, and compositions containing one or more fragments of the spike gene for prophylaxis, diagnostic, and treatment of CCV infections.
Type: Grant
Filed: November 23, 1994
Date of Patent: May 2, 2000
Assignee: Pfizer Inc.
Inventor: Timothy J. Miller, Sharon Klepfer, Albert Paul Reed

Methods For Treating of SARS
Publication number: 20140194500
Abstract: Provided is a method of treating SARS in mammals. The method includes administering a therapeutically effective amount of at least one composition selected from the group consisting of myricetin, scutellarein and a pharmaceutically acceptable salt thereof to a mammal in need of treatment of SARS diseases to suppress the activities of SARS coronavirus helicase.
Type: Application
Filed: January 8, 2013
Publication date: July 10, 2014
Inventor: Young-Sam Keum, Yong-Joo Jeong, Mi-Sun Yu, Young-Won Chin

Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
Abstract: The invention relates to methods for treating or inhibiting SARS-CoV infection involving the administration of an interferon, particularly IFN ?-n1, IFN ?-n3, human leukocyte IFN ? or IFN ?-1b.
Type: Grant
Filed: June 9, 2004
Date of Patent: January 27, 2009
Assignee: Genome Institute of Singapore
Inventor: Emily Li Chuan Tan, Lawrence W. Stanton

TREATMENT OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
Publication number: 20190262432
Abstract: The present disclosure provides novel compositions and methods for treating an infection by MERS-CoV. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by MERS-CoV.
Type: Application
Filed: March 5, 2019
Publication date: August 29, 2019
Inventor: Ronald B. Moss

MERS-CoV vaccine
Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
Type: Grant
Filed: June 29, 2018
Date of Patent: February 4, 2020
Inventor: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai

MERS-CoV vaccine
Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
Type: Grant
Filed: November 26, 2014
Date of Patent: July 10, 2018
Inventor: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai

Assay for Sars Coronavirus by Amplification and Detection of the Replicase Sequence
Publication number: 20080044816
Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.
Type: Application
Filed: September 13, 2004
Publication date: February 21, 2008
Applicant: BECTON, DICKINSON AND COMPANY
Inventor: Jianrong Lou, James A. Price, Daretta A. Yursis, David M. Wolfe, Lisa M. Keller, Tobin J. Hellyer

Assay for sars coronavirus by amplification and detection of nucleocapsid rna sequence
Publication number: 20100136513
Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the nucleocapsid gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARSCoV infection.
Type: Application
Filed: September 13, 2004
Publication date: June 3, 2010
Inventor: Jianrong Lou, James A. Price, JR., Daretta A. Yursis, David M. Wolfe, Lisa M. Keller, Tobin J. Hellyer

Compositions for Canine Respiratory Disease Complex
Publication number: 20140079733
Abstract: Provided herein are compositions comprising a canine influenza virus and a canine respiratory coronavirus. They can further comprise Bordetella bronchiseptica, pertactin, canine parainfluenza virus, and canine adenovirus serotype 2. The compositions are effective for treating or preventing canine respiratory diseases, including canine infectious respiratory disease complex.
Type: Application
Filed: February 3, 2012
Publication date: March 20, 2014
Inventor: Omar Yousif Abdelmagid, Joseph Michael Bricker, Shelly Lynn Shields

Vaccine Against Sars
Publication number: 20080206283
Abstract: The present invention provides nucleotide sequences from SARS (Serve Acute Respiratory Syndrome) coronavirus genomes, as well as the applications of the partial fragments thereof in preparing DNA vaccine or expressing corresponding proteins. Furthermore, the present invention also provides the uses of said proteins in preventing and treating diseases, and preparing antibodies.
Type: Application
Filed: June 17, 2004
Publication date: August 28, 2008
Inventor: Xiangjun Zhou, John Y. Dong

Canine coronavirus S gene and uses therefor
Publication number: 20020127245
Abstract: The present invention provides the amino acid and nucleotide sequences of a CCV spike gene, and compositions containing one or more fragments of the spike gene and encoded polypeptide for prophylaxis, diagnostic purposes and treatment of CCV infections.
Type: Application
Filed: October 5, 2001
Publication date: September 12, 2002
Inventor: Timothy J. Miller, Sharon Klepfer, Albert Paul Reed, Elaine Jones

Epizootic catarrhal enteritis prevention, treatment and diagnosis
Publication number: 20040038202
Abstract: The present invention relates to the use of novel nucleotide sequences for the spike peptide, pol region peptide and M and N region peptide of the ferret coronavirus and derivative products for the diagnosis and treatment of epizootic catarrhal enteritis (ECE) in ferrets.
Type: Application
Filed: January 30, 2003
Publication date: February 26, 2004
Applicant: Michigan State University
Inventor: Roger K. Maes, Annabel G. Wise, Matti Kiupel

HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES
Publication number: 20150238489
Abstract: Methods, uses, medicaments, and unit doses for treating viral diseases are described herein. The methods, uses, medicaments, and unit doses include (a) substituted piperidine and piperazine carboxamides, or a pharmaceutically acceptable salt thereof and (b) one or more pharmaceutically acceptable carriers, excipients or diluents, or combinations thereof. Viral diseases include hepatitis C virus, HIV, BVDV, and Coronavirus infections.
Type: Application
Filed: August 30, 2013
Publication date: August 27, 2015
Inventor: Eliezer Huberman

Compositions and methods for treatment of sever acute respiratory syndrome (sars)
Publication number: 20060263847
Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
Type: Application
Filed: May 20, 2004
Publication date: November 23, 2006
Inventor: George Siber

Method and means for detection of severe acute respiratory syndrome
Publication number: 20050037338
Abstract: A diagnostic means and method of detecting the presence or the absence of severe acute respiratory syndrome coronavirus antibody in a test sample. The means comprises a solid support, an unlabeled recombinant antigen peptide on a first area of the solid support, a labeled recombinant antigen peptide on a second area of the solid support and an internal control antibody peptide on a third area of the solid phase. The first area is located between the second and the third area.
Type: Application
Filed: August 14, 2003
Publication date: February 17, 2005
Inventor: Kuo-Tang Tseng

Compositions for canine respiratory disease complex
Abstract: Provided herein are compositions comprising a canine influenza virus and a canine respiratory coronavirus. They can further comprise Bordetella bronchiseptica, pertactin, canine parainfluenza virus, and canine adenovirus serotype 2. The compositions are effective for treating or preventing canine respiratory diseases, including canine infectious respiratory disease complex.
Type: Grant
Filed: February 3, 2012
Date of Patent: August 23, 2016
Assignee: Zoetis Services LLC
Inventor: Omar Yousif Abdelmagid, Joseph Michael Bricker, Shelly Lynn Shields

Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The Viruses' Glycoproteins
Publication number: 20150150878
Abstract: The disclosure provides methods and compositions useful for inhibiting virus requiring membrane fusion for viral entry, specifically for inhibiting severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), Hendra (HeV) and Nipah (NIV) viruses by targeting Cathepsin-L (CatL) cleavages sites in the viruses' glycoproteins.
Type: Application
Filed: April 4, 2013
Publication date: June 4, 2015
Inventor: Bellur S. Prabhakar, Hatem A. Elshabrawy

Assay for SARS coronavirus by amplification and detection of the replicase sequence
Publication number: 20090258340
Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.
Type: Application
Filed: February 3, 2009
Publication date: October 15, 2009
Applicant: Becton, Dickinson and Company
Inventor: Jianrong Lou, James A. Price, JR., Daretta A. Yursis, David M. Wolfe, Lisa M. Keller, Tobin Hellyer

COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS
Publication number: 20150196578
Abstract: Therapeutics which employ a combination of an antiviral agent and an EP4 receptor agonist for the treatment of human respiratory diseases associated with viral infections are described. Viral infections may include an influenza A virus, for example H1N1, H3N2 and H5N1, and mutations thereof, and/or a coronavirus, for example a virus that causes severe acute respiratory syndrome, “SARS”.
Type: Application
Filed: December 10, 2014
Publication date: July 16, 2015
Inventor: William J. Guilford, Daryl H. Faulds

Canine coronavirus S gene and uses therefor
Abstract: The present invention provides the amino acid and nucleotide sequences of a CCV spike gene, and compositions containing one or more fragments of the spike gene and encoded polypeptide for prophylaxis, diagnostic purposes and treatment of CCV infections.
Type: Grant
Filed: October 5, 2001
Date of Patent: August 5, 2003
Assignee: Pfizer Inc.
Inventor: Timothy J. Miller, Sharon Klepfer, Albert Paul Reed, Elaine V. Jones

Heterocyclyl carboxamides for treating viral diseases
Abstract: Methods, uses, medicaments, and unit doses for treating viral diseases are described herein. The methods, uses, medicaments, and unit doses include (a) substituted piperidine and piperazine carboxamides, or a pharmaceutically acceptable salt thereof and (b) one or more pharmaceutically acceptable carriers, excipients or diluents, or combinations thereof. Viral diseases include hepatitis C virus, HIV, BVDV, and Coronavirus infections.
Type: Grant
Filed: August 30, 2013
Date of Patent: December 6, 2016
Assignee: NovaDrug, LLC
Inventor: Eliezer Huberman

Compositions and methods for treatment of Severe Acute Respiratory Syndrome (SARS)
Publication number: 20040235047
Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
Type: Application
Filed: May 20, 2003
Publication date: November 25, 2004
Inventor: George R. Siber

Antigenic peptides of SARS coronavirus and uses thereof
Publication number: 20060154243
Abstract: The present invention pertains to antigenic peptides of SARS-CoV and their use in diagnostic test methods and in the treatment of condition resulting from SARS-CoV. Furthermore, this invention provides antibodies capable of specifically recognizing the peptides of the invention. The antibodies can also advantageously be used in diagnostic test methods and in the treatment of conditions resulting from SARS-CoV.
Type: Application
Filed: January 20, 2006
Publication date: July 13, 2006
Inventor: Jan Ter Meulen, Jaap Goudsmit, Peter Timmerman, Jelle Slootstra

Canine coronavirus S gene and uses therefor
Abstract: The present invention provides the amino acid and nucleotide sequences of a CCV spike gene, and compositions containing one or more fragments of the spike gene and encoded polypeptide for prophylaxis, diagnostic purposes and treatment of CCV infections.
Type: Grant
Filed: January 28, 2000
Date of Patent: April 16, 2002
Assignee: Pfizer Inc.
Inventor: Timothy J. Miller, Sharon Klepfer, Albert Paul Reed, Elaine V. Jones

SARS CoV main protease inhibitors
Publication number: 20060019967
Abstract: This invention relates to a method for modulating activity of SARS CoV main protease or an analogue thereof by contacting the protein with an effective amount of a compound of the following formula: A1-L-A2 wherein A1, A2, and L are defined herein, and use of the compound in treating coronavirus infection, hepatitis C virus infection, hemophilia, vascular restenosis, or hypertension.
Type: Application
Filed: July 20, 2005
Publication date: January 26, 2006
Inventor: Su-Ying Wu, Hsing-Pang Hsieh, Tsu-An Hsu, I-Lin Lu

Methods of Screening for Respiratory Synctial Virus and Human Metapneumovirus
Publication number: 20100041019
Abstract: Provided are nucleic acid primers and probes for use in diagnostic assays to screen for respiratory infections, such as respiratory syncytial virus (“RSV”) and human metapneumovirus (hMPV). The primers and probes may be used to screen for RSV or hMPV in a singleplex assay or they may be used in a multiplex assay to simultaneously screen for RSV and hMPV, or RSV and/or hMPV and any of the following viruses: influenza A, and influenza B, parainfluenza viruses, adenovirus, coronavirus, and rhinoviruses.
Type: Application
Filed: October 2, 2007
Publication date: February 18, 2010
Inventor: Jill Detmer, Sukhwinder Sangha, Charlene Bush-Donovan

Peptide-based diagnostic reagents for SARS
Publication number: 20050214748
Abstract: The present invention is directed to antigenic peptides and peptide compositions selected from the Membrane glycoprotein (M), the Spike glycoprotein (S), and the Nucleocapsid (N) protein antigens of the SARS coronavirus (SCoV). The present invention is also directed to methods of use of the peptides of the invention, e.g., for the detection of SARS-associated antibodies. Detection methods include enzyme-linked immunosorbent assay (ELISA) or other immunoassay procedures.
Type: Application
Filed: November 8, 2004
Publication date: September 29, 2005
Inventor: Chang Wang, Xinde Fang, Tseng Chang, Scott Liu, Shugene Lynn, Charles Sia

Compositions for the diagnosis and treatment of epizootic catarrhal enteritis in ferrets
Abstract: The present invention relates to the use of novel nucleotide sequences for the M and N region peptide of the ferret coronavirus and derivative products for the diagnosis and treatment of epizootic catarrhal enteritis (ECE) in ferrets.
Type: Grant
Filed: January 30, 2003
Date of Patent: August 14, 2007
Assignee: The Board of Trustees Operating Michigan State University
Inventor: Roger K. Maes, Annabel G. Wise, Matti Kiupel

Binding molecules against SARS-coronavirus and uses thereof
Publication number: 20060121580
Abstract: The present invention provides binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules.
Type: Application
Filed: January 20, 2006
Publication date: June 8, 2006
Inventor: Jan Ter Meulen, Cornelis De Kruif, Edward Van Den Brink, Jaap Goudsmit

METHODS FOR THE DETECTION OF RESPIRATORY VIRUSES
Publication number: 20100086908
Abstract: The present invention relates generally to the field of nucleic acid detection and more specifically to the detection of human respiratory viruses in a patient sample. In some aspects, the invention relates to the detection of multiple respiratory viral groups, including rhinovirus, respiratory syncytial virus, parainfluenza virus, influenza virus, metapneumovirus, adenovirus, coronavirus, and enterovirus.
Type: Application
Filed: May 16, 2008
Publication date: April 8, 2010
Inventor: James R. Prudent, David J. Marshall, Wai-Ming Lee, James Gern, Michael J. Moser, Edward L. Beaty, Gerda Harms

Antiviral Compositions And Methods Of Using The Same
Publication number: 20070259844
Abstract: Pharmaceutical compositions for and methods of preventing infection or treating an individual who has been identified as being infected with a Flavivirus, Pestivirus, picornovirus or coronavirus such as HCV, GB virus B, JEV, WNV, CSFV, BDV, BVDV, poliovirus, FMDV, or EMCV, comprising administering to the individual a therapeutically effective amount of one or more glucocorticoid receptor antagonist compounds, wherein said compound has steroidal structure are disclosed.
Type: Application
Filed: June 21, 2004
Publication date: November 8, 2007
Applicant: VGX PHARMACEUTICALS
Inventor: Jong Kim

METHODS OF TREATING ZIKA VIRUS, MERS-COV, CHIKUNGUNYA, VENEZUELAN EQUINE ENCEPHALITUS, AND RHINOVIRUS IN MAMMALIAN PATIENTS
Publication number: 20170157219
Abstract: Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against Zika virus, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), Chikungunya virus, Venezuelan equine encephalitis, and rhinovirus-14 are disclosed.
Type: Application
Filed: February 9, 2017
Publication date: June 8, 2017
Applicant: Tamir Biotechnology, Inc.
Inventor: Thomas W. Hodge, III

Use of Inhibitors of the Renin-Angiotensin System for the Treatment of Lung Injuries
Publication number: 20080159962
Abstract: The invention relates to the use of Angiotensin Converting enzyme 2 (ACE2) for the preparation of a medicament for the treatment of severe acute lung injury, especially induced by acid aspiration or sepsis, of lung oedemas and lung injuries and failures connected with infection with severe acute respiratory Syndrome (SARS) Coronavirus.
Type: Application
Filed: May 19, 2006
Publication date: July 3, 2008
Applicant: IMBA-INSTITUTE FUR MOLEKULARE BIOTECHNOLOGIE GMBH
Inventor: Josef Penninger, Yumiko Imai, Keiji Kuba, Chengyu Jiang

Assay for SARS coronavirus by amplification and detection of the replicase sequence
Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.
Type: Grant
Filed: February 3, 2009
Date of Patent: May 25, 2010
Assignee: Becton, Dickinson and Company
Inventor: Jianrong Lou, James A. Price, Jr., Daretta A. Yursis, David M. Wolfe, Lisa M. Keller, Tobin Hellyer

Assay system and methods for detecting SARS-CV
Publication number: 20050003340
Abstract: The present invention relates to an assay system and methods for detecting SARS coronavirus (SARS-CV) from the samples (especially for urine) of suspected patient in the control of SARS to provide updated information of prognosis as well as the criteria for discharging a recovered patient from a hospital. The present invention also relates to an apparatus for performing the integration of thermal and magnetic control in the same apparatus to largely reduce the time of hybridization less than 20 minutes and the whole process of SARS-CV detection is less than 5 hours.
Type: Application
Filed: July 1, 2003
Publication date: January 6, 2005
Inventor: George Chou

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY
Publication number: 20190201352
Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.
Type: Application
Filed: March 12, 2019
Publication date: July 4, 2019
Inventor: KATHERINE L. RADTKE, HANNAH PETERS, JOHAN NEYTS, DIRK JOCHMANS, ERIC J. SNIJDER

Peptide-based diagnostic reagents for SARS
Publication number: 20050100883
Abstract: The present invention is directed to antigenic peptides and peptide compositions selected from the Membrane glycoprotein (M), the Spike glycoprotein (S), and the Nucleocapsid (N) protein antigens of the SARS coronavirus (SCoV). The present invention is also directed to methods of use of the peptides of the invention, e.g., for the detection of SARS-associated antibodies. Detection methods include enzyme-linked immunosorbent assay (ELISA) or other immunoassay procedures.
Type: Application
Filed: November 12, 2003
Publication date: May 12, 2005
Inventor: Chang Wang, Xinde Fang, Tseng Chang, Scott Liu, Shugene Lynn, Charles Sia

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY
Publication number: 20180303768
Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.
Type: Application
Filed: July 2, 2018
Publication date: October 25, 2018
Inventor: KATHERINE L. RADTKE, HANNAH PETERS, JOHAN NEYTS, DIRK JOCHMANS, ERIC J. SNIJDER

Assay for SARS coronavirus by amplification and detection of the replicase sequence
Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.
Type: Grant
Filed: September 13, 2004
Date of Patent: April 21, 2009
Assignee: Becton, Dickinson and Company
Inventor: Jianrong Lou, James A. Price, Jr., Daretta A. Yursis, David M. Wolfe, Lisa M. Keller, Tobin J. Hellyer

COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS
Publication number: 20120190637
Abstract: Therapeutics which employ a combination of an antiviral agent and an EP4 receptor agonist for the treatment of human respiratory diseases associated with viral infections are described. Viral infections may include an influenza A virus, for example H1N1, H3N2 and H5N1, and mutations thereof, and/or a coronavirus, for example a virus that causes severe acute respiratory syndrome, “SARS”.
Type: Application
Filed: October 13, 2010
Publication date: July 26, 2012
Applicant: GEMMUS PHARMA, INC.
Inventor: William J. Guilford, Daryl H. Faulds

Antigenic peptides of SARS coronavirus and uses thereof
Publication number: 20060110803
Abstract: The present invention pertains to antigenic peptides of SARS-CoV and their use in diagnostic test methods and in the treatment of condition resulting from SRAS-CoV. Furthermore, this invention provides antibodies capable of specifically recognizing the peptides of the invention. The antibodies can also advantageously be used in diagnostic test methods and in the treatment of condition resulting from SRAS-CoV.
Type: Application
Filed: December 6, 2005
Publication date: May 25, 2006
Applicant: Crucell Holland B.V.
Inventor: Jan Ter Meulen, Jaap Goudsmit, Wouter Puijk, Jelle Slootstra, Peter Timmerman

IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODS
Publication number: 20160206729
Abstract: Disclosed herein are nanoparticles containing MERS virus proteins in polymer structures, and compositions containing the nanoparticles formulated for administration as immunogenic compositions. Also provided herein are vector constructs encoding the proteins, and host cells containing the vector constructs. The disclosure also includes methods of making the nanoparticles and administering them to vertebrates, including methods of inducing immune responses to MERS that reduce or prevent infection by the virus.
Type: Application
Filed: September 19, 2014
Publication date: July 21, 2016
Inventor: Gale SMITH, Ye LIU, Michael MASSARE

SUPPRESSION OF VIRUSES INVOLVED IN RESPIRATORY INFECTION OR DISEASE
Publication number: 20100286238
Abstract: The present invention concerns methods and reagents useful in decreasing the level of or severity of respiratory infection or disease due to paramyxoviruses, such as RSV or HPIV, or coronavirus infection. Particularly, the invention relates to modulating gene expression using a multitargeting interfering RNA molecules that target multiple target sites on one or more pre-selected RNA molecules.
Type: Application
Filed: May 14, 2008
Publication date: November 11, 2010
Inventor: Laurent Pierre Rivory, Michael Poidinger, Donald John Birkett, Gregory Martin Arndt, Toby Passioura

RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF
Publication number: 20180258151
Abstract: This invention provides a method for treating upper respiratory tract infection in a subject, comprising administering to the subject an effective amount of a recombinant interferon, wherein the recombinant interferon has the amino acid sequence of SEQ ID NO:1 and is encoded by the nucleotide sequence SEQ ID NO:2. The upper respiratory tract infection can be induced by various viruses such as rhinovirus, coronavirus, respiratory syncytial virus, influenza, parainfluenza, adenoviruses, coxsackie virus, corona virus and enterovirus.
Type: Application
Filed: March 2, 2018
Publication date: September 13, 2018
Inventor: Guangwen WEI

Novel Five-Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis Therapeutics
Publication number: 20120046337
Abstract: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing ?- and ?-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human ?-hexosaminidase, a new target for development of osteoarthritis therapeutics.
Type: Application
Filed: February 24, 2011
Publication date: February 23, 2012
Inventor: Pi-Hui Liang, Yi-Ling Lin, Chi-Huey Wong

MEANS AND METHODS FOR DISTINGUISHING FECV AND FIPV
Publication number: 20130071833
Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.
Type: Application
Filed: January 18, 2011
Publication date: March 21, 2013
Applicant: Universiteit Utrecht Holding B.V.
Inventor: Petrus Josephus Marie Rottier, Hui-Wen Chang, Herman F. Egberink

Novel Five-Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis Therapeutics
Publication number: 20090306174
Abstract: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing ?- and ?-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human ?-hexosaminidase, a new target for development of osteoarthritis therapeutics.
Type: Application
Filed: December 5, 2006
Publication date: December 10, 2009
Applicant: Academia Sinica
Inventor: Pi-Hui Liang, Yi-Ling Lin, Chi-Huey Wong

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY
Publication number: 20180015052
Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.
Type: Application
Filed: January 28, 2016
Publication date: January 18, 2018
Inventor: KATHERINE L. RADTKE, HANNAH L. PETERS, JOHAN NEYTS, DIRK JOCHMANS, ERIC J. SNIJDER

Isolation and diagnosis of coronaviruses as a factor in bovine shipping fever, and a cell line for culturing both those and other bovine coronaviruses
Abstract: Coronaviruses can be a significant factor in bovine shipping fever. A new human rectal tumor cell line, HRT-18G, is suitable as a host cell line for the propagation of these bovine respiratory coronavirus-shipping fever viruses, and also is well suited for the propagation of other bovine coronaviruses.
Type: Grant
Filed: November 26, 1996
Date of Patent: October 14, 1997
Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Inventor: Johannes Storz

Antisense antiviral agent and method for treating ssRNA viral infection
Publication number: 20030224353
Abstract: The invention provides antisense antiviral compounds and methods of their use in inhibition of growth of viruses of the picornavirus, calicivirus, togavirus, coronavirus, and flavivirus families, as in treatment of a viral infection. The antisense antiviral compounds are substantially uncharged oligomers having a targeting base sequence that is substantially complementary to a viral target sequence which spans the AUG start site of the first open reading frame of the viral genome.
Type: Application
Filed: April 24, 2003
Publication date: December 4, 2003
Inventor: David A. Stein, Douglas E. Skilling, Patrick L. Iversen, Alvin W. Smith

Methods for treatment of severe acute respiratory syndrome (SARS)
Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
Type: Grant
Filed: May 20, 2003
Date of Patent: February 22, 2011
Assignee: Wyeth Holdings Corporation
Inventor: George R. Siber

Antigenic peptides of SARS coronavirus and uses thereof
Publication number: 20070128217
Abstract: The present invention pertains to antigenic peptides of SARS-CoV and their use in diagnostic test methods and in the treatment of condition resulting from SARS-CoV. Furthermore, this invention provides antibodies capable of specifically recognizing the peptides of the invention. The antibodies can also advantageously be used in diagnostic test methods and in the treatment of condition resulting from SARS-CoV.
Type: Application
Filed: January 13, 2006
Publication date: June 7, 2007
Applicant: Crucell Holland B.V.
Inventor: Jan ter Meulen, Jaap Goudsmit, Jelle Slootstra, Peter Timmerman, Cornelis de Kruif, Edward van den Brink

Means and methods for distinguishing FECV and FIPV
Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.
Type: Grant
Filed: January 18, 2011
Date of Patent: October 24, 2017
Assignee: UNIVERSITEIT UTRECHT HOLDING B.V.
Inventor: Petrus Josephus Marie Rottier, Hui-wen Chang, Herman F. Egberink

Corona-virus-like particles comprising functionally deleted genomes
Publication number: 20040071709
Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutics, and vaccines derived thereof. Methods are shown for at least in part inhibiting anti-parallel coiled coil formation of a coronavirus spike protein wherein the methods include decreasing the contact between heptad repeat regions of the protein. The invention provides a peptide including a heptad repeat region of a corona viral spike protein and/or a functional fragment and/or an equivalent thereof. The invention also provides antibodies and inhibiting compounds.
Type: Application
Filed: April 14, 2003
Publication date: April 15, 2004
Inventor: Petrus Josephus Marie Rottier, Berend-Jan Bosch

CORONAVIRUSES, VACCINES COMPRISING THE SAME, AND METHODS FOR PREVENTING DISEASE
Publication number: 20180333482
Abstract: Coronaviruses, vaccines comprising the same, and methods for preventing disease. One embodiment of such includes a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a non-structural protein (nsp)-15, the replicase gene encoding the nsp15 and causes any change, including mutations and/or deletions, that affects the stability or activity of the nsp15.
Type: Application
Filed: March 2, 2018
Publication date: November 22, 2018
Inventor: Susan Baker, Xufang Deng, Matthew Hackbart, Robert Mettelman, Anna Mielech, Amornrat O'Brien, Kay Faaberg, Kelly Milton Lager

Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses
Publication number: 20050004071
Abstract: This invention relates to methods for treating, preventing or managing coronavirus infections in mammals using sulfated polysaccharides. More particularly, this invention relates to methods of treating, preventing or managing infection by coronaviruses, particularly viral infections leading to or causing diseases such as the newly discovered Severe Acute Respiratory Syndrome (“SARS”). The invention involves the use of sulfated polysaccharides which are abundant, non-toxic and inexpensive and which are potent antivirals in vivo.
Type: Application
Filed: April 20, 2004
Publication date: January 6, 2005
Inventor: Wayne Comper

Compositions and methods for treatment of severe acute respiratory syndrome (SARS)
Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
Type: Grant
Filed: May 20, 2004
Date of Patent: May 25, 2010
Assignee: Wyeth
Inventor: George R. Siber

Canine coronavirus vaccine
Abstract: A vaccine for protecting canine animals from disease caused by infection with canine corona virus (CCV) which comprises an effective amount of the cell-associated CCV peplomer protein. A polyvalent vaccine comprising an effective amount of cell-associated CCV peplomer protein and an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed.
Type: Grant
Filed: June 8, 1987
Date of Patent: February 27, 1990
Assignee: Norden Laboratories, Inc.
Inventor: Michael A. Gill, Stephen W. May

Methods For Diagnosing Feline Coronavirus Infections
Publication number: 20150031018
Abstract: Provided is a method for determining whether a feline is infected with pathogenic Feline Infectious Peritonitis Virus (FIPV) or Feline Enteric Infection Virus (FECV). The method involves determining the presence or absence of intact or mutated S1/S2 and S2? cleavage sites in the spike protein of serotype 1 feline coronaviruses (FCoV1). The presence of both intact cleavage sites is indicative of FECV. The presence of a mutation in one or both cleavage sites is indicative of FIPV. The absence of both sites is indicative of an absence of FCoV1 infection. Compositions for use in determining infection and kits are also provided.
Type: Application
Filed: September 25, 2014
Publication date: January 29, 2015
Inventor: Gary Whittaker, Andrew Regan

SARS virus nucleotide and amino acid sequences and uses thereof
Abstract: The invention provides, in part, the genomic sequence of a putative coronavirus, the SARS virus, and provides novel nucleic acid and amino acid sequences that may be used, for example, for the diagnosis, prophylaxis, or therapy of a variety of SARS virus related disorders.
Type: Grant
Filed: April 28, 2004
Date of Patent: March 1, 2011
Assignee: The Public Health Agency of Canada
Inventor: Frank Plummer, Heinz Feldmann, Steven Jones, Yan Li, Nathalie Bastien, Robert Conrad Brunham, Angela Brooks-Wilson, Robert Holt, Christopher Upton, Rachel Roper, Caroline Astell, Steven Jones

Binding molecules against SARS-coronavirus and uses thereof
Abstract: The present invention provides binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules are capable of specifically binding to SARS-CoV and can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from SARS-CoV.
Type: Grant
Filed: January 20, 2006
Date of Patent: April 13, 2010
Assignee: Crucell Holland B.V.
Inventor: Jan H. Ter Meulen, Cornelis A. De Kruif, Edward N. Van Den Brink, Jaap Goudsmit

Isolation and diagnosis of coronaviruses as a factor in bovine shipping fever, and a cell line for culturing both those and other bovine coronaviruses
Abstract: Coronaviruses can be a significant factor in bovine shipping fever. A new human rectal tumor cell line, HRT-18G, is suitable as a host cell line for the propagation of these bovine respiratory coronavirus-shipping fever viruses, and also is well suited for the propagation of other bovine coronaviruses.
Type: Grant
Filed: June 15, 1994
Date of Patent: December 3, 1996
Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Inventor: Johannes Storz

Sars Virus Nucleotide and Amino Acid Sequences and Uses Thereof
Publication number: 20070258999
Abstract: The invention provides, in part, the genomic sequence of a putative coronavirus, the SARS virus, and provides novel nucleic acid and amino acid sequences that may be used, for example, for the diagnosis, prophylaxis, or therapy of a variety of SARS virus related disorders.
Type: Application
Filed: April 28, 2004
Publication date: November 8, 2007
Applicant: THE PUBLIC HEALTH AGENCY OF CANADA
Inventor: Frank Plummer, Heinz Feldmann, Steven Jones, Yan Li, Nathalie Bastien, Robert Brunham, Angela Brooks-Wilson, Robert Holt, Christopher Upton, Rachel Roper, Caroline Astell, Steven Jones

Diagnostics for sars virus
Publication number: 20070092938
Abstract: This invention relates to Severe Acute Respiratory Syndrome associated coronavirus (SARS virus) isolated and recombinant proteins, in particular the nucleocapsid (N) protein and spike (S) protein, as well as fragments thereof and their use in the diagnosis, treatment and prevention of Severe Acute Respiratory Syndrome (SARS). The proteins and fragments carry epitopes that are specific for the SARS virus. Thus, detection methods based on these proteins or fragments as well as the monoclonal antibodies against these proteins or fragments are specific for the SARS virus.
Type: Application
Filed: February 4, 2004
Publication date: April 26, 2007
Applicant: Temasek Life Sciences Laboratory
Inventor: Jimmy Kwang, Ai Ling, Eng Ooi, Hiok Chng

PROTEASE TRANSITION STATE INHIBITOR PRODRUGS
Publication number: 20190151400
Abstract: Disclosed herein are protease transition state inhibitor/analogue prodrug compounds selected from the group consisting of esters, carbamates, ester phosphates, and pharmaceutically acceptable salts thereof. Compositions containing such prodrugs are also disclosed, along with methods of using such compounds therapeutically or prophylactically against calicivirus, picornavirus, and/or coronavirus infection, as well as other conditions, such as malaria, cancer, stroke, heart attack, neural degeneration, cataracts, and glaucoma through inhibition of the variety of proteases associated with progression of such conditions.
Type: Application
Filed: July 28, 2017
Publication date: May 23, 2019
Inventor: Kyeong-Ok Chang, William C. Groutas

Agent For The Prophylaxis And Treatment Of Highly Pathogenic Infectious Diseases
Publication number: 20120129908
Abstract: The invention relates to an agent for the treatment and/or prophylaxis of highly pathogenic infectious diseases, such as highly pathogenic influenza A (in particular, subtypes H5 and H7) and severe acute respirator syndrome caused by the genotype IV coronavirus. The agent is in the form of glutaryl histamine or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on glutaryl histamine or a pharmaceutically acceptable salt thereof and to a method for the treatment and/or prophylaxis of highly pathogenic infectious diseases.
Type: Application
Filed: May 10, 2010
Publication date: May 24, 2012
Inventor: Vladimir Evgenievich Nebolsin, Galina Alexandrovna Zheltukhina, Sergey Vladimirovich Borisevich, Svetlana Yakovlevna Loginova, Alexander Grigorievich Chuchalin

MACROCYCLIC LACTONE COMBINATION COMPOSITIONS, VACCINES AND METHODS FOR PRODUCING SAME
Publication number: 20100266628
Abstract: An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at least one inactivated viral component derived from rotavirus and/or coronavirus; (b) a macrocyclic lactone active compound; and (c) a pharmaceutically acceptable parenteral carrier and preservative. The injectable compositions which include eprinomectin result in extremely low milk residues.
Type: Application
Filed: April 13, 2010
Publication date: October 21, 2010
Inventor: Majid Razzak, Robert Holmes

Five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics
Abstract: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing ?- and ?-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human ?-hexosaminidase, a new target for development of osteoarthritis therapeutics.
Type: Grant
Filed: December 5, 2006
Date of Patent: April 5, 2011
Assignee: Academia Sinica
Inventor: Pi-Hui Liang, Yi-Ling Lin, Chi-Huey Wong

Agent for the prophylaxis and treatment of highly pathogenic infectious diseases
Abstract: The invention relates to an agent for the treatment and/or prophylaxis of highly pathogenic infectious diseases, such as highly pathogenic influenza A (in particular, subtypes H5 and H7) and severe acute respirator syndrome caused by the genotype IV coronavirus. The agent is in the form of glutaryl histamine or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on glutaryl histamine or a pharmaceutically acceptable salt thereof and to a method for the treatment and/or prophylaxis of highly pathogenic infectious diseases.
Type: Grant
Filed: May 10, 2010
Date of Patent: November 29, 2016
Assignee: LTD “Valenta-Intellekt”
Inventor: Vladimir Evgenievich Nebolsin, Galina Alexandrovna Zheltukhina, Sergey Vladimirovich Borisevich, Svetlana Yakovlevna Loginova, Alexander Grigorievich Chuchalin

Methods For Diagnosing Feline Coronavirus Infections
Publication number: 20130045886
Abstract: Provided is a method for determining whether a feline is infected with pathogenic Feline Infectious Peritonitis Virus (FIPV) or Feline Enteric Infection Virus (FECV). The method involves determining the presence or absence of intact or mutated S1/S2 and S2? cleavage sites in the spike protein of serotype 1 feline coronaviruses (FCoV1). The presence of both intact cleavage sites is indicative of FECV. The presence of a mutation in one or both cleavage sites is indicative of FIPV. The absence of both sites is indicative of an absence of FCoV1 infection. Compositions for use in determining infection and kits are also provided.
Type: Application
Filed: March 8, 2011
Publication date: February 21, 2013
Inventor: Gary Whittaker, Andrew Regan

Binding molecules against SARS-coronavirus and uses thereof
Publication number: 20100172917
Abstract: Described are binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules, and methods of identifying or producing the binding molecules. The binding molecules are capable of specifically binding to SARS-CoV, and can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from SAR.
Type: Application
Filed: November 16, 2009
Publication date: July 8, 2010
Applicant: Crucell Holland B.V.
Inventor: Jan H. Ter Meulen, Cornelis A. De Kruif, Edward N. Van Den Brink, Jaap Goudsmit

Macrocyclic lactone combination compositions, vaccines and methods for producing same
Abstract: An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at least one inactivated viral component derived from rotavirus and/or coronavirus; (b) a macrocyclic lactone active compound; and (c) a pharmaceutically acceptable parenteral carrier and preservative. The injectable compositions which include eprinomectin result in extremely low milk residues.
Type: Grant
Filed: April 13, 2010
Date of Patent: November 20, 2012
Assignee: Merial Limited
Inventor: Majid Razzak, Robert Holmes

Assay system and methods for detecting SARS-CV
Abstract: The present invention relates to an assay system and methods for detecting SARS coronavirus (SARS-CV) from the samples (especially for urine) of suspected patient in the control of SARS to provide updated information of prognosis as well as the criteria for discharging a recovered patient from a hospital. The present invention also relates to an apparatus for performing the integration of thermal and magnetic control in the same apparatus to largely reduce the time of hybridization less than 20 minutes and the whole process of SARS-CV detection is less than 5 hours.
Type: Grant
Filed: July 1, 2003
Date of Patent: July 1, 2008
Assignee: AsiaGEN Corporation
Inventor: George Chin-Sheng Chou

ANTIVIRAL COMPOSITION COMPRISING A SULFATED POLYSACCHARIDE
Publication number: 20120237572
Abstract: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus, The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.
Type: Application
Filed: May 30, 2012
Publication date: September 20, 2012
Applicant: MARINOMED BIOTECHNOLOGIE GMBH
Inventor: Andreas GRASSAUER, Eva PRIESCHL-GRASSAUER

Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
Abstract: Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.
Type: Grant
Filed: June 10, 2015
Date of Patent: March 20, 2018
Assignee: TAMIR BIOTECHNOLOGY, INC.
Inventor: Thomas W. Hodge, III

ANTIVIRAL COMPOSITION COMPRISING A SULFATED POLYSACCHARIDE
Publication number: 20110059919
Abstract: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.
Type: Application
Filed: August 22, 2008
Publication date: March 10, 2011
Applicant: MARINOMED BIOTECHNOLOGIE GMBH
Inventor: Andreas Grassauer, Eva Prieschl-Grassauer

Five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics
Abstract: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing ?- and ?-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human ?-hexosaminidase, a new target for development of osteoarthritis therapeutics.
Type: Grant
Filed: February 24, 2011
Date of Patent: September 25, 2012
Assignee: Academia Sinica, Taiwan
Inventor: Pi-Hui Liang, Yi-Ling Lin, Chi-Huey Wong

Antiviral composition comprising a sulfated polysaccharide
Abstract: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.
Type: Grant
Filed: May 30, 2012
Date of Patent: July 9, 2019
Assignee: MARINOMED BIOTECH AG
Inventor: Andreas Grassauer, Eva Prieschl-Grassauer

Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity
Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.
Type: Grant
Filed: January 28, 2016
Date of Patent: August 28, 2018
Inventor: Katherine L. Radtke, Hannah L. Peters, Johan Neyts, Dirk Jochmans, Eric J. Snijder

Method For Prophylaxis or Treatment of Feline Infectious Peritonitis
Publication number: 20110142797
Abstract: Provided is a method for treatment and/or prophylaxis of FIP in cats. The method is performed by administering to a cat a composition comprising a therapeutic and/or prophylactic amount of a cysteine protease inhibitor. The cysteine protease inhibitor can be a selective cathepsin B inhibitor. Also provided is a method for inhibiting FIPV replication. The method comprises contacting a cell infected with FIPV with a cysteine protease inhibitor in an amount effective to inhibit replication of FIPV. It is expected the method will be effective for therapy or prophylaxis of FIP in any species of cat and will be effective against any strain of feline coronavirus.
Type: Application
Filed: April 2, 2009
Publication date: June 16, 2011
Inventor: Gary R. Whittaker, Andrew D. Regan

Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences
Publication number: 20040009942
Abstract: The invention provides methods of preventing and/or treating infection by a respiratory virus such as respiratory syncytial virus (RSV) and SARS-associated coronavirus, particularly reducing infection and/or one or more symptoms of respiratory virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being exposed to a respiratory virus, has been exposed to a respiratory virus or is infected with a respiratory virus. The ISS is administered without any antigens of the respiratory virus. Administration of the ISS results in reduced incidence and/or severity of one or more symptoms of respiratory virus infection.
Type: Application
Filed: April 29, 2003
Publication date: January 15, 2004
Inventor: Gary Van Nest

METHODS OF TREATING VIRAL INFECTIONS, PARTICULARLY RABIES, MERS-COV, INFLUENZA, EBOLA, CHIKUNGUNYA, VENEZUELAN EQUINE ENCEPHALITUS, CANINE PARVOVIRUS, ADENOVIRUS, RESPIRATORY SYNCYTIAL VIRUS, RHINOVIRUS, AND POXVIRUS IN MAMMALIAN PATIENTS
Publication number: 20150376584
Abstract: Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.
Type: Application
Filed: June 10, 2015
Publication date: December 31, 2015
Applicant: TAMIR BIOTECHNOLOGY, INC.
Inventor: Thomas W. Hodge, III

Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity
Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.
Type: Grant
Filed: July 2, 2018
Date of Patent: March 12, 2019
Inventor: Katherine L. Radtke, Hannah Peters, Johan Neyts, Dirk Jochmans, Eric J. Snijder

SARS-coronavirus virus-like particles and methods of use
Publication number: 20050002953
Abstract: The present disclosure describes a system for making SARS-CoV-virus-like particles (SARS-CoV-VLPs) comprising one or more recombinant vectors which express the SARS-CoV E-protein, the SARS-CoV M-protein, and the SARS-CoV S-protein. Additionally, the present disclosure describes methods of inducing an immune response in a subject comprising administering to the subject a nucleic acid encoding the SARS-CoV E-protein, the SARS-CoV M-protein, and the SARS-CoV S-protein. Methods of inducing an immune response in a subject comprising administering to the subject SARS-CoV-VLPs are also disclosed.
Type: Application
Filed: May 4, 2004
Publication date: January 6, 2005
Inventor: Jens Herold

Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
Publication number: 20060258611
Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
Type: Application
Filed: June 14, 2006
Publication date: November 16, 2006
Inventor: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Lin, Ying Peng

Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
Publication number: 20050004063
Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
Type: Application
Filed: May 19, 2004
Publication date: January 6, 2005
Inventor: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Lin, Ying Peng

Multi-allelic molecular detection of sars-associated coronavirus
Publication number: 20070042351
Abstract: The subject invention relates to a multiple-allelic RT-real-time polymerase chain reaction (PCR) assay for coronaviruses including the SARS virus. Multiple target sequences within the SARS-CoV, S, E, M and N genes are identified. The use of the four different targets enhances the likelihood that the fundamental genetic drift of the virus will not lead to a false negative result. Multiplex assays format for the assay are envisioned. Thus, the present invention allows for early diagnosis of a SARS infection. The assay would be useful in the context of monitoring treatment regimens, screening potential anti SARS agents, and similar applications requiring qualitative and quantitative determinations.
Type: Application
Filed: August 13, 2004
Publication date: February 22, 2007
Inventor: Leondios Kostrikis

Method for prophylaxis or treatment of feline infectious peritonitis
Abstract: Provided is a method for treatment and/or prophylaxis of FIP (feline infectious peritonitis) in cats. The method is performed by administering to a cat a composition comprising a therapeutic and/or prophylactic amount of a cysteine protease inhibitor. The cysteine protease inhibitor can be a selective cathepsin B inhibitor. Also provided is a method for inhibiting FIPV (Feline infectious peritonitis virus) replication. The method comprises contacting a cell infected with FIPV with a cysteine protease inhibitor in an amount effective to inhibit replication of FIPV. It is expected the method will be effective for therapy or prophylaxis of FIP in any species of cat and will be effective against any strain of feline coronavirus.
Type: Grant
Filed: April 2, 2009
Date of Patent: June 2, 2015
Assignee: Cornell University
Inventor: Gary R. Whittaker, Andrew D. Regan

VIRAL PROTEASE
Publication number: 20070160981
Abstract: An isolated polypeptide comprising a sequence that includes X?5-X?4-X?3-X?2-X?1-X+1, wherein X?5 is Arg, Ala, Ser, or Glu; X?4 is Leu; X?3 is Lys, Ala, Gln, or Asn; X?2 is Gly or Ala; X?1 is Gly; and X+1 is Ala, Gly, Asn, Val, or Lys; and the polypeptide, upon contact with SARS-CoV PLP2, murine hepatitis virus PLP, or bovine coronavirus PLP, is cleaved between residues X?1 and X+1 Also disclosed are related nucleic acids, vectors, host cells, screening methods, and treatment methods.
Type: Application
Filed: October 23, 2006
Publication date: July 12, 2007
Inventor: Xin Chen, Yu San Han, Tsu-An Hsu

Microarray for pathogen identification
Publication number: 20070092871
Abstract: There is disclosed a microarray device for pathogen identification and for subtyping influenza A. Pools of primers are disclosed and used to amplify any subtype of influenza A. Pathogen identification includes influenza A, influenza B, parainfluenza virus, adenovirus, enterovirus, rhinovirus, human metapneumovirus, respiratory syncytal virus, herpes simplex viruses, SARS coronavirus, Epstein-Barr virus, human herpes virus, pan bacteria, Chlamydia, Mycoplasma, streptococcus, Bacillus anthracis, Streptococcuspyogenes, Mycoplasmapneumoniae, Chlamydiapneumoniae, Bacillus thuringiensis, Bacillus subtilis, Bacillus cereus, and B. anthracis. The probes are preferably selected from the first 500 nt of a gene from the 5? end. The primers are preferably selected from bases in the 500 to 600 nt range from the 5? end.
Type: Application
Filed: October 20, 2006
Publication date: April 26, 2007
Inventor: Michael Lodes, Dominic Suciu

Compositions and methods for treating viral infections
Publication number: 20060198823
Abstract: The present invention provides methods of treating a virus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological virus infection, that has clinical sequelae. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and a Type II interferon receptor agonist for the treatment of a virus infection, and co-administering an amount of an additional non-pirfenidone/pirfenidone analog agent effective to reduce or eliminate the occurrence or severity of side effects normally associated with the administration of the interferon receptor agonists.
Type: Application
Filed: March 31, 2004
Publication date: September 7, 2006
Inventor: Lawrence Blatt

Immunoconjugates for treatment of infectious diseases
Publication number: 20100266620
Abstract: The present invention features immunoconjugates which comprise therapeutic agents coupled to antibodies that specifically recognize pathogen surface antigens. These immunoconjugates can be used to treat or prevent infectious diseases. Upon administration of an immunoconjugate of the present invention to an infected host, the immunoconjugate binds to a specific antigen on the surface of the targeted pathogen (e.g., virus). As the pathogen enters the host cells, the therapeutic agent(s) in the immunoconjugate destroys the infected host cells (and, preferably, the bound pathogen), thereby preventing the replication and transmission of the pathogen. In one embodiment, the immunoconjugates of the present invention specifically recognize surface/envelope antigens of the following viruses: HIV, HBV, HCV, EBV, influenza virus, and SARS associated coronavirus.
Type: Application
Filed: January 19, 2007
Publication date: October 21, 2010
Inventor: Le Sun

Multi-allelic molecular detection of SARS-associated coronavirus
Publication number: 20060003340
Abstract: The subject invention relates to a multiple-allelic RT-real-time polymerase chain reaction (PCR) assay for coronaviruses including the SARS virus. Multiple target sequences within the SARS-CoV, S, E, M and N genes are identified. The use of the four different targets enhances the likelihood that the fundamental genetic drift of the virus will not lead to a false negative result. Multiplex assays format for the assay are envisioned. Thus, the present invention allows for early diagnosis of a SARS infection. The assay would be useful in the context of monitoring treatment regimens, screening potential anti SARS agents, and similar applications requiring qualitative and quantitative determinations.
Type: Application
Filed: August 13, 2004
Publication date: January 5, 2006
Applicant: Birch Biomedical Research, LLC
Inventor: Leondios Kostrikis

Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
Type: Grant
Filed: June 14, 2006
Date of Patent: September 30, 2008
Assignee: The University of Hong Kong
Inventor: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Chia-Mi Lin, Ying Peng

Lyme combination compositions and uses
Abstract: Disclosed and claimed are compositions containing a Borrelia burgdorferi antigen, and methods for making and using them. The antigen can be OspA. The compositions can contain at least one additional antigen from a pathogen other than Borrelia burgdorferi. The compositions are useful for eliciting an immunological response in a host mammal susceptible to Lyme Disease and to the mammalian pathogen other than Borrelia burgdorferi. Suitable host mammals include dogs, pups, horses, and, the additional antigen can be of a canine, equine or feline pathogen, such as rabies, canine distemper, adenovirus, coronavirus, parainfluenza and parvovirus. No significant efficacy interference is observed.
Type: Grant
Filed: March 5, 1997
Date of Patent: April 9, 2002
Assignee: Merial Limited
Inventor: Judy Jarecki-Black

PORCINE CORONAVIRUS VACCINES
Publication number: 20200038504
Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with corona virus infection including porcine epidemic diarrhea virus (PEDV) and/or porcine deltacorona virus (PDCoV). The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen, and/or an adjuvant inactivated/killed PDCoV (e.g., chemically inactivated PDCoV virus), and/or recombinant PDCoV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and/or PDCoV and methods of producing the porcine epidemic diarrhea virus and/or porcine deltacorona virus vaccine are also provided.
Type: Application
Filed: January 26, 2018
Publication date: February 6, 2020
Inventor: Scott ACKERMAN, Joseph Ralph HERMANN, Luis Alejandro HERNANDEZ, Lea Ann HOBBS, Arun V. IYER, Sean O'CONNER, Abby Rea PATTERSON, Eric Martin VAUGHN, Joseph Gilbert VICTORIA

Glycopeptide antibiotic derivatives
Publication number: 20050250677
Abstract: Novel glycopeptide antibiotic derivatives, processes for their preparation, their use as a medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections are provided. The present invention relates to the use of glycopeptide antibiotics and their semisynthetic derivatives to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses belonging to Retroviridae, Herpes viridae, Flaviviridae and the Coronaviridae, like HIV (human immunodeficiency virus), HCV (hepatitis C virus), BVDV (bovine viral diarrhoea virus), SARS (severe acute respiratory syndrome) causing virus, FCV (feline coronavirus), HSV (herpes simplex virus), VZV (varicella zoster virus) and CMV (cytomegalovirus).
Type: Application
Filed: September 1, 2003
Publication date: November 10, 2005
Inventor: Jan Balzarini, Maria Preobrazhenskaya, Erik De Clercq

Multi-allelic detection of SARS-associated coronavirus
Abstract: The subject invention relates to a multiple-allelic RT-real-time polymerase chain reaction (PCR) assay for coronaviruses including the SARS virus. Multiple target sequences within the SARS-CoV, S, E, M and N genes are identified. The use of the four different targets enhances the likelihood that the fundamental genetic drift of the virus will not lead to a false negative result. Multiplex assays format for the assay are envisioned. Thus, the present invention allows for early diagnosis of a SARS infection. The assay would be useful in the context of monitoring treatment regimens, screening potential anti SARS agents, and similar applications requiring qualitative and quantitative determinations.
Type: Grant
Filed: August 13, 2004
Date of Patent: May 4, 2010
Assignee: Birch Biomedical Research LLC
Inventor: Leondios G. Kostrikis

Canine vaccines against Bordetella bronchiseptica
Publication number: 20050089533
Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention relates to vaccines and methods for protecting dogs against disease caused by Leptospira bratislava. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona.
Type: Application
Filed: October 6, 2004
Publication date: April 28, 2005
Inventor: Joseph Frantz, Cassius Tucker, Thomas Newby

Human antibodies to middle east respiratory syndrome—coronavirus spike protein
Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
Type: Grant
Filed: May 20, 2015
Date of Patent: August 1, 2017
Assignee: Regeneron Pharmaceuticals, Inc.
Inventor: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam

Anti-Sars Monoclonal Antibodies
Publication number: 20080081047
Abstract: Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.
Type: Application
Filed: December 6, 2004
Publication date: April 3, 2008
Inventor: Jody Berry, Steven Jones, Xin Yong Yuan, Mike Gubbins, Anton Andonov, Hana Weingartl, Mike Drebot, Frank Plummer

Human antibodies to Middle East Respiratory Syndrome—coronavirus spike protein
Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
Type: Grant
Filed: June 26, 2017
Date of Patent: September 10, 2019
Assignee: Regeneron Pharmaceuticals, Inc.
Inventor: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam

Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
Type: Grant
Filed: May 19, 2004
Date of Patent: October 31, 2006
Assignee: The University of HongKong
Inventor: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Chia-Mi Lin, Ying Peng

Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals
Publication number: 20040019022
Abstract: A method for treating cellular and tissue damage is disclosed. The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid and salts thereof in the prevention and treatment of dysfunction, damage, and/or injuries to organs, tissues and/or cells in human or animal subjects caused by diseases, infections and conditions such as pneumonia, coronavirus, multiple transfusions, trauma, ischemic-reperfusion dysfunctions, stroke, drug overdose, and severe acute respiratory syndrome. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in combination with other therapeutic agents such as antibiotics. The acid may be administered in any practical delivery form, and in free acid or buffered form.
Type: Application
Filed: July 18, 2003
Publication date: January 29, 2004
Inventor: Karen Stec, Israel Rubinstein, David Eiznhamer, Ze-Qu Xu, Michael Flavin

CANINE VACCINES
Publication number: 20080175860
Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention relates to vaccines and methods for protecting dogs against disease caused by Leptospira bratislava. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona.
Type: Application
Filed: December 21, 2007
Publication date: July 24, 2008
Inventor: Joseph Frantz, Cassius McAllister Tucker, Thomas Jack Newby

Canine vaccines against Bordetella bronchiseptica
Publication number: 20040185062
Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.
Type: Application
Filed: January 29, 2004
Publication date: September 23, 2004
Inventor: Paul J. Dominowski, Joseph C. Frantz, Richard L. Krebs, Shelly L. Shields, Robert Greg Sorensen

Baicalin and its derivatives as a treatment for SARS coronavirus infection or other related infections
Publication number: 20050215494
Abstract: The present invention relates to a pharmaceutical composition useful for the treatment of diseases associated with viruses of the order Nidovirales of the family Coronaviradae, such as Severe Acute Respiratory Syndrome (SARS) viruses in humans and other animals. In particular, this invention relates to a naturally occurring compound, namely, baicalin, extracted and purified from the Chinese medicinal plant Scutellaria baicalensis Georgi (Chinese name: Huang Qin), that exhibits potent antiviral activity against members of the order Nidovirales of the family Coronaviradae that infects humans and other animals; in particular, SARS viruses in humans (“hSARS virus”). The invention also relates to a therapeutic method, using pharmaceutical compositions comprising baicalin compounds, for the treatment, amelioration, management or prevention of diseases associated with members of the order Nidovirales of the family Coronaviradae, such as hSARS.
Type: Application
Filed: November 8, 2004
Publication date: September 29, 2005
Inventor: Kwok Yuen, Feng Chen, Kwok Chan, Yi Kao, Yi Guan, Leo Poon, Jsm Peiris

MUCOSAL ADJUVANT COMPOSITION
Publication number: 20130302360
Abstract: Problem to be Solved: The present invention provides a novel mucosal adjuvant. Solution: The present invention provides a mucosal adjuvant composition containing at least a composition comprising molecules having a molecular weight in a range of 100 to 300 kDa obtained from cells or culture fluid of Bordetella bronchiseptica. Administration of the mucosal adjuvant composition to a non-human animal at a surface of the mucous membrane can enhance immunity at the surface of mucous membrane. Therefore preventive effects against trans-mucosal infection can be increased by administering an inactivated vaccine against trans-mucosal infection and the mucosal adjuvant composition to a non-human animal at a surface of mucous membrane. The present invention is effective for preventing trans-mucosal infections, including one or more infections of e.g., canine parainfluenza, canine adenovirus, canine coronavirus, canine parvovirus, canine distemper virus, canine herpesvirus, reovirus and pneumovirus.
Type: Application
Filed: September 27, 2011
Publication date: November 14, 2013
Applicant: KYORITSU SEIYAKU CORPORATION
Inventor: Ken-ichi Asai, Kazuo Kawakami, Masami Mochizuki

CANINE COMBINATION VACCINES
Publication number: 20080226670
Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.
Type: Application
Filed: November 20, 2007
Publication date: September 18, 2008
Inventor: Paul J. Dominowski, Joseph C. Frantz, Richard L. Krebs, Shelly L. Shields, Robert Greg Sorensen

Anti-SARS monoclonal antibodies
Abstract: Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterization of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.
Type: Grant
Filed: December 6, 2004
Date of Patent: November 24, 2009
Inventor: Jody Berry, Steven Jones, Xin Yong Yuan, Mike Gubbins, Anton Andonov, Hana Weingartl, Mike Drebot, Frank Plummer

Infectious clones
Publication number: 20100167352
Abstract: The present invention relates to methods of preparing a DNA comprising steps, wherein (a) a DNA comprising a full length copy of the genomic RNA (gRNA) or an RNA virus; or (b) a DNA comprising one or several fragments of a gRNA of an RNA virus, which fragments code for an RNA dependent RNA polymerase and at least one structural or non-structural protein; or (c) a DNA having a homology of at least 60% to the sequences of (a) or (b); is cloned into a bacterial artificial chromosome (BAC). Additionally, DNAs are provided, which comprise sequences derived from the genomic RNA (gRNA) of a coronavirus which sequences have a homology of at least 60% to the natural sequence of the virus and code for an RNA dependent RNA polymerase and at least one structural or no-structural protein, wherein a fragment of said DNA is capable of being transcribed into RNA which RNA can be assembled to a virion.
Type: Application
Filed: September 30, 2008
Publication date: July 1, 2010
Inventor: Luis Enjuanes Sanchez

Mucosal adjuvant composition
Abstract: Problem to be Solved: The present invention provides a novel mucosal adjuvant. Solution: The present invention provides a mucosal adjuvant composition containing at least a composition comprising molecules having a molecular weight in a range of 100 to 300 kDa obtained from cells or culture fluid of Bordetella bronchiseptica. Administration of the mucosal adjuvant composition to a non-human animal at a surface of the mucous membrane can enhance immunity at the surface of mucous membrane. Therefore preventive effects against trans-mucosal infection can be increased by administering an inactivated vaccine against trans-mucosal infection and the mucosal adjuvant composition to a non-human animal at a surface of mucous membrane. The present invention is effective for preventing trans-mucosal infections, including one or more infections of e.g., canine parainfluenza, canine adenovirus, canine coronavirus, canine parvovirus, canine distemper virus, canine herpesvirus, reovirus and pneumovirus.
Type: Grant
Filed: September 27, 2011
Date of Patent: July 5, 2016
Assignee: KYORITSU SEIYAKU CORPORATION
Inventor: Ken-ichi Asai, Kazuo Kawakami, Masami Mochizuki

Antibodies to SARS coronavirus
Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV S protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
Type: Grant
Filed: May 21, 2007
Date of Patent: June 1, 2010
Assignee: Amgen, Inc.
Inventor: John S. Babcook, Bellur S. Prabhakar, Melissa Coughlin

Canine combination vaccines
Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.
Type: Grant
Filed: November 20, 2007
Date of Patent: June 15, 2010
Assignee: Pfizer Inc.
Inventor: Paul J. Dominowski, Joseph C. Frantz, Richard L. Krebs, Shelly L. Shields, Robert Greg Sorensen

Infectious clones
Publication number: 20030148325
Abstract: The present invention relates to methods of preparing a DNA comprising steps, wherein (a) a DNA comprising a full length copy of the genomic RNA (gRNA) or an RNA virus; or (b) a DNA comprising one or several fragments of a gRNA of an RNA virus, which fragments code for an RNA dependent RNA polymerase and at least one structural or non-structural protein; or (c) a DNA having a homology of at least 60% to the sequences of (a) or (b); is cloned into a bacterial artificial chromosome (BAC). Additionally, DNAs are provided, which comprise sequences derived from the genomic RNA (gRNA) of a coronavirus which sequences have a homology of at least 60% to the natural sequence of the virus and code for an RNA dependent RNA polymerase and at least one structural or no-structural protein, wherein a fragment of said DNA is capable of being transcribed into RNA which RNA can he assembled to a virion.
Type: Application
Filed: September 11, 2002
Publication date: August 7, 2003
Inventor: Luis Enjuanes Sanchez

1,2-dithiins having antifungal activity
Abstract: Novel 1,2-dithiin compounds useful as antifungal or anti-infective agents, as well as methods for their use as such, are described.
Type: Grant
Filed: February 28, 1995
Date of Patent: December 3, 1996
Assignee: Shaman Pharmaceuticals, Inc.
Inventor: Donald E. Bierer, Patricia Peterli-Roth

High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
Publication number: 20050181357
Abstract: The present invention relates to a high-throughput diagnostic assay for the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). In particular, the invention relates to a high-throughput reverse transcription-PCR diagnostic test for SARS associated coronavirus (SARS-CoV). The present assay is a rapid, reliable assay which can be used for diagnosis and monitoring the spread of SARS and is based on the nucleotide sequences of the N (nucleocapsid)-gene of the hSARS virus. The present method eliminates false negative results and provides increased sensitivity for the assay. The invention also discloses the S (spike)-gene of the hSARS virus. The invention further relates to the deduced amino acid sequences of the N-gene and S-gene products of the hSARS virus and to the use of the N-gene and S-gene products in diagnostic methods. The invention further encompasses diagnostic assays and kits comprising antibodies generated against the N-gene or S-gene product.
Type: Application
Filed: March 24, 2004
Publication date: August 18, 2005
Inventor: Joseph Peiris, Kwok Yuen, Lit Poon, Yi Guan, Kwok Chan, John Nicholls, Frederick Leung

Antibodies to SARS coronavirus
Publication number: 20080248043
Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV S protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
Type: Application
Filed: May 21, 2007
Publication date: October 9, 2008
Applicant: Amgen Inc.
Inventor: John S. Babcook, Bellur S. Prabhakar, Melissa Coughlin

Methods for treating viral infections
Abstract: The present invention provides methods for treating viral diseases in humans by administering to an afflicted host pharmaceutical compositions containing a therapeutically effective amount of a combination of ##STR1## in a weight ratio ranging from about 1:1 to about 1:10 (A:B); wherein R is OH, NH.sub.2, OW, or H; X is H, F, Cl, Br, I, OH, OW, NO.sub.2, or NH.sub.2 ; Y is H, F, Cl, Br, or I; W is ##STR2## or a C.sub.1 to C.sub.12 aliphatic group; Z is an aliphatic or aromatic group of C.sub.1 to C.sub.12 ;X and Y can both vary within the compound; or pharmaceutically acceptable salts thereof.Particularly disclosed herein is a composition comprising a 1 to 4 ratio of the sodium salts of phenylacetylglutamine and phenylacetic acid, formulated in both oral and parenteral forms clinically useful in the treatment of herpes virus, HIV, human papilloma virus, rhinovirus, coronavirus, orthomyxovirus and paramyxovirus.
Type: Grant
Filed: May 27, 1992
Date of Patent: September 14, 1993
Inventor: Stanislaw R. Burzynski

Infectious clones
Publication number: 20040086846
Abstract: The present invention relates to methods of preparing a DNA comprising steps, wherein (a) a DNA comprising a full length copy of the genomic RNA (gRNA) or an RNA virus; or (b) a DNA comprising one or several fragments of a gRNA of an RNA virus, which fragments code for an RNA dependent RNA polymerase and at least one structural or non-structural protein; or (c) a DNA having a homology of at least 60% to the sequences of (a) or (b); is cloned into a bacterial artificial chromosome (BAC). Additionally, DNAs are provided, which comprise sequences derived from the genomic RNA (gRNA) of a coronavirus which sequences have a homology of at least 60% to the natural sequence of the virus and code for an RNA dependent RNA polymerase and at least one structural or no-structural protein, wherein a fragment of said DNA is capable of being transcribed into RNA which RNA can be assembled to a virion.
Type: Application
Filed: June 3, 2002
Publication date: May 6, 2004
Inventor: Luis Enjuanes Sanchez

Polynucleotides encoding porcine transmissible gastroenteritis virus
Abstract: The present invention relates to methods of preparing a DNA comprising steps, wherein (a) a DNA comprising a full length copy of the genomic RNA (gRNA) or an RNA virus; or (b) a DNA comprising one or several fragments of a gRNA of an RNA virus, which fragments code for an RNA dependent RNA polymerase and at least one structural or non-structural protein; or (c) a DNA having a homology of at least 60% to the sequences of (a) or (b); is cloned into a bacterial artificial chromosome (BAC). Additionally, DNAs are provided, which comprise sequences derived from the genomic RNA (gRNA) of a coronavirus which sequences have a homology of at least 60% to the natural sequence of the virus and code for an RNA dependent RNA polymerase and at least one structural or non-structural protein, wherein a fragment of said DNA is capable of being transcribed into RNA which RNA can he assembled to a virion.
Type: Grant
Filed: September 11, 2002
Date of Patent: May 6, 2008
Assignee: Consejo Superior de Investigationes Cientificas
Inventor: Luis Enjuanes Sanchez

AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES
Publication number: 20170183318
Abstract: The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
Type: Application
Filed: February 27, 2015
Publication date: June 29, 2017
Inventor: Vladimir Evgenievich NEBOLSIN, Tatyana Alexandrovna KROMOVA

Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
Publication number: 20130216566
Abstract: SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.
Type: Application
Filed: June 21, 2004
Publication date: August 22, 2013
Inventor: D. Karl Anderson, Kathleen M. Holtz-Corris, Rick Chubet, Daniel Adams, Manon Cox

High-Throughput Diagnostic Assay For the Human Virus Causing Severe Acute Respiratory Syndrome (SARS)
Publication number: 20100285457
Abstract: The present invention relates to a high-throughput diagnostic assay for the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). In particular, the invention relates to a high-throughput reverse transcription-PCR diagnostic test for SARS associated coronavirus (SARS-CoV). The present assay is a rapid, reliable assay which can be used for diagnosis and monitoring the spread of SARS and is based on the nucleotide sequences of the N (nucleocapsid)-gene of the hSARS virus. The present method eliminates false negative results and provides increased sensitivity for the assay. The invention also discloses the S (spike)-gene of the hSARS virus. The invention further relates to the deduced amino acid sequences of the N-gene and S-gene products of the hSARS virus and to the use of the N-gene and S-gene products in diagnostic methods. The invention further encompasses diagnostic assays and kits comprising antibodies generated against the N-gene or S-gene product.
Type: Application
Filed: June 12, 2009
Publication date: November 11, 2010
Inventor: Joseph S.M. Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung

Coronavirus-like particles comprising functionally deleted genomes
Publication number: 20050130127
Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines derived therefrom. The invention provides replicative coronaviruses and virus-like particles (VLPs) from which large parts of their genome are (at least functionally) deleted without abolishing their replicative capacities. The deletion preferably results in at least a functional deletion in that the corresponding gene is not or is only partly expressed wherein the resulting gene product is dysfunctional or at least functionally distinct from a corresponding wild-type gene product.
Type: Application
Filed: November 14, 2003
Publication date: June 16, 2005
Inventor: Petrus Rottier, Cornelis De Haan, Bert Haijema, Berend-Jan Bosch

ISOLATION AND CHARACTERIZATION OF THE PRECURSOR VIRUS OF HUMAN SARS VIRUS: SARS-ASSOCIATED CORONA VIRUS-LIKE VIRUS
Publication number: 20080069839
Abstract: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods.
Type: Application
Filed: May 24, 2004
Publication date: March 20, 2008
Inventor: Yi Guan, Bo-Jiang Zheng

1,2-dithiins having antifungal activity
Abstract: Novel 1,2-dithiin compounds useful as antifungal or anti-infective agents, as well as methods for their use as such, are described.
Type: Grant
Filed: February 28, 1995
Date of Patent: July 15, 1997
Assignee: Shaman Pharmaceuticals, Inc.
Inventor: Donald E. Bierer, Jeffrey M. Dener, Joane Litvak, Larisa G. Dubenko

Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
Publication number: 20040259934
Abstract: Infection by a Coronaviridae virus (e.g., a coronavirus) and/or illness due to a Coronaviridae virus are treated or protected against by administration of a therapeutically or prophylactically effective amount of certain nucleoside compounds and derivatives thereof, either alone or in a composition comprising the nucleoside compound or its derivative and a pharmaceutically acceptable carrier. In addition, replication of a Coronaviridae virus is inhibited by administration of the nucleoside compounds and derivatives thereof, either alone or in pharmaceutical compositions. The nucleosides are particularly suitable for use in treating or prophylaxis of an infection by the SARS virus and/or in treating or prophylaxis of SARS, and for use in inhibiting replication of the SARS virus. The nucleoside compounds and derivatives can optionally be administered in combination with other agents active against the Coronaviridae virus and/or an illness due to the virus.
Type: Application
Filed: April 27, 2004
Publication date: December 23, 2004
Inventor: David B. Olsen, Joanne E. Tomassini, Shi-Shan Mao, Steven S. Carroll

3D-Structure model of SARS coronavirus 3CL protease and anti-SARS drugs
Publication number: 20060142383
Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.
Type: Application
Filed: December 2, 2005
Publication date: June 29, 2006
Inventor: Jianhua Shen, Hualiang Jiang, Xu Shen, Jianping Zuo, Xiaomin Luo, Donglu Bai, Jingkang Shen, Kaixian Chen, Chunshan Gui, Lili Chen, Jing Chen, Yifu Yang, Xianhan Zhuang, Yiming Yang, Xuchang He, Hong Liu, Bing Xiong, Haibin Luo, Tao Sun, Fei Ye

Amide compound, methods for preparation, and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
Publication number: 20180362481
Abstract: The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
Type: Application
Filed: August 17, 2018
Publication date: December 20, 2018
Inventor: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova

Recombinant Sars-Cov nsp12 and the Use of Thereof and the Method for Producing it
Publication number: 20110097730
Abstract: The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found.
Type: Application
Filed: June 13, 2008
Publication date: April 28, 2011
Inventor: Jong Won Oh, Dae Gyun Ahn

Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
Abstract: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods.
Type: Grant
Filed: May 24, 2004
Date of Patent: April 22, 2008
Assignee: The University of Hong Kong
Inventor: Yi Guan, Bo-Jiang Zheng

Coronavirus-like particles comprising functionally deleted genomes
Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines derived therefrom. The invention provides replicative coronaviruses and virus-like particles (VLPs) from which large parts of their genome are (at least functionally) deleted without abolishing their replicative capacities. The deletion preferably results in at least a functional deletion in that the corresponding gene is not or is only partly expressed wherein the resulting gene product is dysfunctional or at least functionally distinct from a corresponding wild-type gene product.
Type: Grant
Filed: November 14, 2003
Date of Patent: July 7, 2009
Inventor: Petrus Josephus Marie Rottier, Cornelis Alexander Maria De Haan, Bert Jan Haijema

Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
Abstract: SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.
Type: Grant
Filed: June 21, 2004
Date of Patent: September 24, 2013
Assignee: Protein Sciences Corporation
Inventor: D. Karl Anderson, Kathleen M. Holtz-Corris, Rick Chubet, Daniel Adams, Manon Cox

High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
Abstract: The present invention relates to a high-throughput diagnostic assay for the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). In particular, the invention relates to a high-throughput reverse transcription-PCR diagnostic test for SARS associated coronavirus (SARS-CoV). The present assay is a rapid, reliable assay which can be used for diagnosis and monitoring the spread of SARS and is based on the nucleotide sequences of the N (nucleocapsid)-gene of the hSARS virus. The present method eliminates false negative results and provides increased sensitivity for the assay. The invention also discloses the S (spike)-gene of the hSARS virus. The invention further relates to the deduced amino acid sequences of the N-gene and S-gene products of the hSARS virus and to the use of the N-gene and S-gene products in diagnostic methods. The invention further encompasses diagnostic assays and kits comprising antibodies generated against the N-gene or S-gene product.
Type: Grant
Filed: March 24, 2004
Date of Patent: June 16, 2009
Assignee: The University of Hong Kong
Inventor: Joseph S. M. Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung

INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS
Publication number: 20190241618
Abstract: The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCR??-CD3??-CD3??-?? signaling complex. Yet more specifically, the peptides act on the TCR?/CD3??/?? signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions.
Type: Application
Filed: October 22, 2018
Publication date: August 8, 2019
Inventor: Alexander B. Sigalov

Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it
Abstract: The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found.
Type: Grant
Filed: June 13, 2008
Date of Patent: June 25, 2013
Assignee: Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation
Inventor: Jong Won Oh, Dae Gyun Ahn

Inhibition of TCR signaling with peptide variants
Abstract: The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCR??-CD3??-CD3??-?? signaling complex. Yet more specifically, the peptides act on the TCR?/CD3??/?? signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions.
Type: Grant
Filed: September 30, 2010
Date of Patent: November 27, 2018
Assignee: SIGNABLOK, Inc.
Inventor: Alexander B. Sigalov

3D-structure model of SARS coronavirus 3CL protease and anti-SARS drugs
Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.
Type: Grant
Filed: December 2, 2005
Date of Patent: February 16, 2010
Inventor: Jianhua Shen, Hualiang Jiang, Xu Shen, Jianping Zuo, Xiaomin Luo, Donglu Bai, Jingkang Shen, Kaixian Chen, Chunshan Gui, Lili Chen, Jing Chen, Yifu Yang, Xianhan Zhuang, Yiming Yang, Xuchang He, Hong Liu, Bing Xiong, Haibin Luo, Tao Sun, Fei Ye

Inhibition of TCR signaling with peptide variants
Abstract: The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCR??-CD3??-CD3??-?? signaling complex. Yet more specifically, the peptides act on the TCR?/CD3??/?? signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions.
Type: Grant
Filed: October 22, 2018
Date of Patent: January 21, 2020
Assignee: SIGNABLOK, INC
Inventor: Alexander B. Sigalov

Inhibition of TCR Signaling with Peptide Variants
Publication number: 20130039948
Abstract: The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCR??-CD3??-CD3??-?? signaling complex. Yet more specifically, the peptides act on the TCR?/CD3??/?? signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions.
Type: Application
Filed: September 30, 2010
Publication date: February 14, 2013
Applicant: SIGNABLOK, INC.
Inventor: Alexander B. Sigalov

METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPEUTICS
Publication number: 20160238601
Abstract: The present invention provides methods and compositions for detecting a coronavirus in a sample and identifying the subgroup of the coronavirus in the sample.
Type: Application
Filed: October 14, 2014
Publication date: August 18, 2016
Inventor: Ralph Baric, Sudhakar Agnihothram, Boyd Yount

COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION AND SARS
Publication number: 20090068142
Abstract: The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection.
Type: Application
Filed: July 29, 2008
Publication date: March 12, 2009
Applicant: Three Rivers Pharmaceuticals LLC
Inventor: Lawrence M. BLATT

Compositions and methods for detecting severe acute respiratory syndrome coronavirus
Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
Type: Grant
Filed: November 3, 2003
Date of Patent: October 31, 2006
Inventor: Laura Gillim-Ross, Jill Taylor, David R. Scholl, David E. Wentworth, Joseph D. Jollick

COMPOSITIONS AND METHODS FOR CORONAVIRUS INHIBITION
Publication number: 20140045743
Abstract: The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.
Type: Application
Filed: August 8, 2013
Publication date: February 13, 2014
Inventor: Robert F. GARRY, Russell B. WILSON, I

Anti-coronavirus drug
Publication number: 20060223847
Abstract: The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent.
Type: Application
Filed: July 14, 2004
Publication date: October 5, 2006
Applicant: Arigen, Inc.
Inventor: Nobutaka Fujii, Naoki Yamamoto

Canine respiratory coronavirus (CRCV) spike protein, polymerase and hemagglutinin/esterase
Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
Type: Grant
Filed: July 1, 2003
Date of Patent: August 17, 2010
Assignee: The Royal Veterinary College
Inventor: John Brownlie, Victoria Jane Chalker, Kerstin Erles

Compositions and methods for coronavirus inhibition
Abstract: The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.
Type: Grant
Filed: August 8, 2013
Date of Patent: June 16, 2015
Inventor: Robert F. Garry, Russell B. Wilson

BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE INHIBITORS
Publication number: 20170313685
Abstract: This invention pertains to materials and methods for the treatment of patients with coronavirus infection and the control of zoonotic disease outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors.
Type: Application
Filed: April 28, 2017
Publication date: November 2, 2017
Applicant: Purdue Research Foundation
Inventor: Sarah Emma St. John, Andrew D. Mesecar

Anti-coronavirus vaccine
Publication number: 20050053622
Abstract: The invention relates to a vaccine against coronavirus infections and, in particular, against feline infectious peritonitis (FIP). The inventive vaccine comprises immunogenic peptides included in the S protein of feline coronaviruses (FcoV), which do not result from immunologic enhancement. The invention also relates to the use of at least one peptide for the preparation of a vaccine that induces protection against coronavirus infections, said peptide being selected from the group comprising fragments of an S protein of coronavirus of at least 12 amino acids, included in the SEQ ID NO: 5, or nucleic acid fragments of at least 36 nucleotides, included in the SEQ ID NO: 10 and coding for one of said peptides.
Type: Application
Filed: August 9, 2002
Publication date: March 10, 2005
Inventor: Andre Aubert, Veronique Duquesne, Marc Eloit, Valerie Gonon

Coronavirus
Publication number: 20170216427
Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
Type: Application
Filed: July 23, 2015
Publication date: August 3, 2017
Inventor: Erica Bickerton, Sarah Keep, Paul Britton

Broad-spectrum non-covalent coronavirus protease inhibitors
Abstract: This invention pertains to materials and methods for the treatment of patients with coronavirus infection and the control of zoonotic disease outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors.
Type: Grant
Filed: April 28, 2017
Date of Patent: May 22, 2018
Assignee: PURDUE RESEARCH FOUNDATION
Inventor: Sarah Emma St. John, Andrew D. Mesecar

Compositions Against Sars-Coronavirus and Uses Thereof
Publication number: 20080014204
Abstract: The present invention provides compositions of binding molecules specifically binding to a coronavirus such as SARS-CoV and capable of neutralizing an infection caused by the virus. The compositions are suitable for diagnosing, preventing and/or treating a condition resulting from a coronavirus such as SARS-CoV.
Type: Application
Filed: November 10, 2005
Publication date: January 17, 2008
Inventor: Jan Ter Meulen, Edward Van Den Brink, Cornelis De Kruif, Jaap Goudsmit

Anti-coronavirus drug
Abstract: The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent.
Type: Grant
Filed: July 14, 2004
Date of Patent: February 24, 2009
Assignee: aRigen Pharmaceuticals, Inc.
Inventor: Nobutaka Fujii, Naoki Yamamoto

Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
Abstract: New purified and isolated bovine coronavirus (BCV) types (II and III) are described which can be used to create new modified live vaccines for administration to cattle in order to confer immunity against virulent wild-type bovine coronavirus infection. Preferably, a multivalent modified live vaccine is provided for oral-nasal administration which includes the known Type I virus and the new Types II and III virus. Hygromycin B has also demonstrated to be effective for suppressing BCV replication and thus can be administered to cattle as a treatment for the chronic disease and to suppress shedding of BCV in cattle feces.
Type: Grant
Filed: February 4, 1997
Date of Patent: June 29, 1999
Assignee: Kansas State University Research Foundation
Inventor: Sanjay Kapil

Anti-coronavirus agent
Publication number: 20070026087
Abstract: An antiviral agent is provided which is effective in treating coronaviruses and can be formed into various products whose efficacy sustainability is promising. In particular, the present invention provides an antiviral agent which is effective in treating a coronavirus, comprising a silver ion carrier; a product capable of inactivating a coronavirus, comprising the same; and a method of inactivating a coronavirus. The silver ion carrier is at least one selected from a compound represented by the following formula (1), potassium titanate, potassium uranate, potassium vanadate, potassium niobate, sodium tangustate, magnesium molybdate, calcium pentaborate, aluminosilicate, aluminum phosphate, nickel hexacyanoferrate, sepiolite, montmorillonite, silica gel, zeolite, ?-alumina, titanium oxide hydrate, hydroxyapatite and a glassy carrier. AgaAbM2c(PO4)d.
Type: Application
Filed: October 31, 2003
Publication date: February 1, 2007
Applicant: Toagosei Co., Ltd.
Inventor: Koji Sugiura, Yasuharu Ono

Coronavirus
Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
Type: Grant
Filed: July 23, 2015
Date of Patent: November 20, 2018
Assignee: THE PIRBRIGHT INSTITUTE
Inventor: Erica Bickerton, Sarah Keep, Paul Britton

Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity
Publication number: 20080027006
Abstract: The invention relates to diseases of coronaviruses, particularly severe acute respiratory syndrome (SARS). Compositions and methods in connection with peptide-based compounds are described relating to inhibition or prevention of coronavirus activity including that of SARS coronavirus and the ability of its S protein to achieve fusion with and entry into a target cell.
Type: Application
Filed: February 14, 2005
Publication date: January 31, 2008
Applicant: The Regents of the University of Colorado
Inventor: Brian Tripet, Robert S. Hodges

MERS CORONAVIRUS VACCINE
Publication number: 20190351048
Abstract: The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.
Type: Application
Filed: December 22, 2017
Publication date: November 21, 2019
Inventor: Susanne RAUCH

ATTENUATED BOVINE CORONAVIRUS AND RELATED VACCINES
Publication number: 20170274065
Abstract: The present invention discloses novel attenuated bovine coronavirus isolates, compositions comprising these isolate, and methods of using such compositions in vaccines, including in live vaccines. The present invention further discloses the administration of such vaccines, including the intranasal administration of such vaccines, to aid in the prevention of respiratory disease caused by bovine coronavirus.
Type: Application
Filed: September 2, 2015
Publication date: September 28, 2017
Applicant: Intervet Inc.
Inventor: Catherine M. Peters, Mark W. Mellencamp, Wenzhi Xue, Terri Wasmoen, Emilio Trigo

Canine coronavirus vaccine from feline enteric coronavirus
Abstract: This invention provides a vaccine which contains, per dose, an effective immunizing amount of an inactivated feline enteric coronavirus and a suitable carrier. The vaccine of this invention may also contain an adjuvant, an effective immunizing amount of a second inactivated virus and a an effective immunizing amount of an inactivated bacteria. Additionally provided by this invention is a method of immunizing a dog against disease caused by canine coronavirus involving administering to the dog a dose of the vaccine of this invention. The method of this invention may also involve administering one or more additional doses of vaccine to the dog, immunizing the dog against disease caused by a second virus and immunizing the dog against disease caused by a bacteria.
Type: Grant
Filed: December 8, 1993
Date of Patent: May 12, 1998
Assignee: Solvay Animal Health, Inc.
Inventor: Michael A. Gill

Coronavirus S Peptides
Publication number: 20110178269
Abstract: Isolated polypeptides containing SEQ ID NO: 3 and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.
Type: Application
Filed: February 4, 2008
Publication date: July 21, 2011
Inventor: Yeau-Ching Wang, Szu-Chia Lai, Chia-Tsui Yeh, Pele Choi-Sing Chong, Shih-Jen Liu

Compositions against SARS-coronavirus and uses thereof
Abstract: The present invention provides compositions of binding molecules specifically binding to a coronavirus such as SARS-CoV and capable of neutralizing an infection caused by the virus. The compositions are suitable for diagnosing, preventing and/or treating a condition resulting from a coronavirus such as SARS-CoV.
Type: Grant
Filed: November 10, 2005
Date of Patent: January 31, 2012
Assignee: Crucell Holland B.V.
Inventor: Jan Henrik Ter Meulen, Edward Norbert Van Den Brink, Cornelis Adriaan De Kruif, Jaap Goudsmit

Methods and kits for detecting SARS-associated coronavirus
Publication number: 20040265796
Abstract: The present invention provides a synthetic nucleic acid sequence comprising 10-30 nucleotides of the N gene region and/or the 3′ non-coding region of the SARS-associated coronavirus genome, and a synthetic nucleic acid sequence comprising 10-30 nucleotides of a nucleic acid sequence that is complementary to at least one of those regions. Also provided are compositions comprising the sequences, and uses of the sequences in diagnostic kits. The present invention further provides a primer set for determining the presence or absence of SARS-associated coronavirus in a biological sample, wherein the primer set comprises at least one of the synthetic nucleic acid sequences. Also provided are a composition comprising the primer set, and use of the primer set in a diagnostic kit. Finally, the present invention provides kits and methods for determining the presence or absence of SARS-associated coronavirus in a biological sample.
Type: Application
Filed: January 23, 2004
Publication date: December 30, 2004
Inventor: Thomas Briese, W. Ian Lipkin, Gustavo Palacios, Omar Jabado

Nucleic Acid Sequences That Can Be Used As Primers And Probes In The Amplification And Detection Of Sars Coronavirus
Publication number: 20090226885
Abstract: The present invention is related to nucleic acid sequences that can be used in the field of virus diagnostics, more specifically the diagnosis of infections with a novel human coronavirus causing Severe Acute Respiratory Syndrome (SARS). With the present invention nucleotide sequences are provided that can be used as primers and probes in the amplification and detection of SARS nucleic acid. The oligonucleotide sequences provided with the present invention are located in the replicase gene, the nucleocapsid gene and the 3? end non-coding region of the SARS Coronavirus genome. It has been found that, by using the sequences of the present invention in methods for the amplification and detection of nucleic acid a sensitive and specific detection of SARS Coronavirus can be obtained. The oligonucleotide sequences according to the present invention are especially useful in methods for the amplification of nucleic acid.
Type: Application
Filed: March 8, 2004
Publication date: September 10, 2009
Inventor: P.T.G Sillekens, Marlieke Overdijk, Saskia van de Laar

Coronavirus S peptides
Publication number: 20060199176
Abstract: Isolated polypeptides containing SEQ ID NO: 3 and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.
Type: Application
Filed: July 14, 2005
Publication date: September 7, 2006
Inventor: Yeau-Ching Wang, Szu-Chia Lai, Chia-Tsui Yeh, Pele Chong, Shih-Jen Liu

Attenuated bovine coronavirus and related vaccines
Abstract: The present invention discloses novel attenuated bovine coronavirus isolates, compositions comprising these isolate, and methods of using such compositions in vaccines, including in live vaccines. The present invention further discloses the administration of such vaccines, including the intranasal administration of such vaccines, to aid in the prevention of respiratory disease caused by bovine coronavirus.
Type: Grant
Filed: September 2, 2015
Date of Patent: October 8, 2019
Assignee: Intervet Inc.
Inventor: Catherine M. Peters, Mark W. Mellencamp, Wenzhi Xue, Terri Wasmoen, Emilio Trigo

Nucleic acid sequence comprising the rna packaging signal of a group 1 coronavirus and the applications thereof
Publication number: 20050152920
Abstract: The invention relates to a nucleic acid sequence comprising the RNA packaging signal of a group 1 coronavirus, such as transmissible gastroenteritis virus of swine (TGEV), which is located between nucleotides 100 and 649 of the genome of said coronavirus. The inventive sequence can be employed to produce viral vectors for use in basic and applied research, for example, in developing systems of expressing products of interest, vaccine vectors and gene therapy.
Type: Application
Filed: January 24, 2003
Publication date: July 14, 2005
Inventor: Luis Sanchez, David Escors Murugarren, Javier Ortego Alonso

Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines
Abstract: Nucleic acid sequences encoding the Bovine Coronavirus E2 (or BCV S) and E3 (or BCV HE) structural glycoproteins and methods of producing these proteins, including recombinant expression, e.g., in mammalian or insect cells, are provided. The E2 and E3 proteins or antigenic fragments thereof are useful components for Bovine Coronavirus vaccines and methods of treatment.
Type: Grant
Filed: December 22, 1993
Date of Patent: September 30, 1997
Assignee: Veterinary Infectious Disease Organization
Inventor: Michael D. Parker, Graham J. Cox, Lorne A. Babiuk

METHOD FOR DETECTING SARS CORONAVIRUS
Publication number: 20090092962
Abstract: This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.
Type: Application
Filed: June 10, 2008
Publication date: April 9, 2009
Applicant: EIKEN KAGAKU KABUSHIKI KAISHA
Inventor: Harumi Minekawa, Keiko Watanabe, Shinichi Kojiya

Methods of Treating Coronavirus Infection
Publication number: 20170027975
Abstract: The present invention provides methods for treating a coronavirus infection. For example, treatment may be effected by administering a neurotransmitter inhibitor, a signaling kinase inhibitor, an estrogen receptor inhibitor, a DNA metabolism inhibitor or an anti-parasitic agent. Also provided are methods for treating a coronavirus infection in which an anti-viral drug also is administered during any of the described methods.
Type: Application
Filed: April 7, 2015
Publication date: February 2, 2017
Inventor: Matthew Frieman, Peter B. Jarhling, Lisa E. Hensley

METHOD FOR DETECTING SARS CORONAVIRUS
Publication number: 20090117537
Abstract: This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.
Type: Application
Filed: June 10, 2008
Publication date: May 7, 2009
Applicant: EIKEN KAGAKU KABUSHIKI KAISHA
Inventor: Harumi MINEKAWA, Keiko Watanabe, Shinichi Kojiya

Method for detecting sars coronavirus
Publication number: 20070099178
Abstract: This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.
Type: Application
Filed: June 15, 2004
Publication date: May 3, 2007
Applicant: EIKEN KAGAKU KABUSHIKI KAISHA
Inventor: Harumi Minekawa, Keiko Watanabe, Shinichi Kojiya

Nucleic acid sequences that can be used as primers and probes in the amplification and detection of SARS coronavirus
Abstract: The present invention is related to nucleic acid sequences that can be used in the field of virus diagnostics, more specifically the diagnosis of infections with a novel human coronavirus causing Severe Acute Respiratory Syndrome (SARS). With the present invention nucleotide sequences are provided that can be used as primers and probes in the amplification and detection of SARS nucleic acid. The oligonucleotide sequences provided with the present invention are located in the replicase gene, the nucleocapsid gene and the 3? end non-coding region of the SARS Coronavirus genome. It has been found that, by using the sequences of the present invention in methods for the amplification and detection of nucleic acid a sensitive and specific detection of SARS Coronavirus can be obtained. The oligonucleotide sequences according to the present invention are especially useful in methods for the amplification of nucleic acid.
Type: Grant
Filed: March 8, 2004
Date of Patent: January 31, 2012
Assignee: Biomerieux, B.V.
Inventor: Peter T. G. Sillekens, Marlieke Overdijk, Saskia van de Laar

HOMOPIPERAZINE COMPOUNDS THAT INHIBIT RIBOSOMAL FRAMESHIFTING BY BINDING TO RNA PSEUDOKNOT STRUCTURE OF SARS CORONAVIRUS
Publication number: 20080207597
Abstract: Provided is a homopiperazine compound for inhibiting ribosomal frameshifting by binding to an RNA pseudoknot structure of SARS coronavirus. Particularly, the present invention provides a pharmaceutical composition for inhibiting synthesis of protein induced by ?1 frameshifting by binding to an RNA pseudoknot structure specifically existing in SARS coronavirus. The composition includes a therapeutically effective amount of homopiperazine compound of following chemical formula 1 or a pharmaceutically accepted salt thereof, and a pharmaceutically accepted carrier or excipient.
Type: Application
Filed: December 20, 2007
Publication date: August 28, 2008
Applicant: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION
Inventor: Hyun-Ju PARK, So-Jung PARK, Yang-Gyun KIM

Methods of treating coronavirus infection
Abstract: The present invention provides methods for treating a coronavirus infection. For example, treatment may be effected by administering a neurotransmitter inhibitor, a signaling kinase inhibitor, an estrogen receptor inhibitor, a DNA metabolism inhibitor or an anti-parasitic agent. Also provided are methods for treating a coronavirus infection in which an anti-viral drug also is administered during any of the described methods.
Type: Grant
Filed: April 7, 2015
Date of Patent: October 8, 2019
Inventor: Matthew Frieman, Peter B. Jarhling, Lisa E. Hensley

Methods and kits for detecting SARS-associated coronavirus
Abstract: The present invention provides a synthetic nucleic acid sequence comprising 10-30 nucleotides of the N gene region and/or the 3? non-coding region of the SARS-associated coronavirus genome, and a synthetic nucleic acid sequence comprising 10-30 nucleotides of a nucleic acid sequence that is complementary to at least one of those regions. Also provided are compositions comprising the sequences, and uses of the sequences in diagnostic kits. The present invention further provides a primer set for determining the presence or absence of SARS-associated coronavirus in a biological sample, wherein the primer set comprises at least one of the synthetic nucleic acid sequences. Also provided are a composition comprising the primer set, and use of the primer set in a diagnostic kit. Finally, the present invention provides kits and methods for determining the presence or absence of SARS-associated coronavirus in a biological sample.
Type: Grant
Filed: January 23, 2004
Date of Patent: September 1, 2009
Assignee: The Trustees of Columbia University In the City of New York
Inventor: Thomas Briese, W. Ian Lipkin, Gustavo Palacios, Omar Jabado

Method for detecting SARS coronavirus
Abstract: This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.
Type: Grant
Filed: June 10, 2008
Date of Patent: September 29, 2009
Assignee: Eiken Kagaku Kabushiki Kaisha
Inventor: Harumi Minekawa, Keiko Watanabe, Shinichi Kojiya

Method for detecting SARS coronavirus
Abstract: This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.
Type: Grant
Filed: June 15, 2004
Date of Patent: July 15, 2008
Assignee: Eiken Kagaku Kabushiki Kaisha
Inventor: Harumi Minekawa, Keiko Watanabe, Shinichi Kojiya

Method for detecting SARS coronavirus
Abstract: This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.
Type: Grant
Filed: June 10, 2008
Date of Patent: September 29, 2009
Assignee: Eiken Kagaku Kabushiki Kaisha
Inventor: Harumi Minekawa, Keiko Watanabe, Shinichi Kojiya

COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION
Publication number: 20160082074
Abstract: The invention relates to the use of non-immunosuppressive cyclophilin inhibitors in the treatment of Coronavirus infection in a patient.
Type: Application
Filed: May 8, 2015
Publication date: March 24, 2016
Applicant: LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Inventor: Nikolai Naoumov, Albrecht von Brunn

METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS
Publication number: 20180296584
Abstract: Provided are methods of treating feline Coronavirus infections comprising administering a therapeutically effective amount of a compound of Compound 1 to Compound 9, or a pharmaceutically acceptable salt thereof
Type: Application
Filed: March 13, 2018
Publication date: October 18, 2018
Inventor: Michel Joseph Perron

Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 inhibiting the swine influenza (SIV) and transmissible gastroenteritis coronavirus (tgev)
Publication number: 20060178341
Abstract: The present invention relates to the soluble glucan oligomer having a M.W. ranging from 1,000 to 10,000 prepared by treating insoluble beta-glucan isolated the cell wall of yeast variant IS2 with commercially available beta-glucan hydrolyzing enzymes. The soluble glucan oligomer showed potent efficacy on inhibiting activity of influenza virus and transmissible gastroenteritis coronavirus, therefore, it can be used as the therapeutics or health care food for treating and preventing mammal's diseases caused by the infection of influenza virus and transmissible gastroenteritis coronavirus.
Type: Application
Filed: June 23, 2004
Publication date: August 10, 2006
Inventor: Won Kook Moon, Dong Kim, Jeong Park, Bong Chung

Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus
Abstract: Provided is a homopiperazine compound for inhibiting ribosomal frameshifting by binding to an RNA pseudoknot structure of SARS coronavirus. Particularly, the present invention provides a pharmaceutical composition for inhibiting synthesis of protein induced by ?1 frameshifting by binding to an RNA pseudoknot structure specifically existing in SARS coronavirus. The composition includes a therapeutically effective amount of homopiperazine compound of following chemical formula 1 or a pharmaceutically accepted salt thereof, and a pharmaceutically accepted carrier or excipient.
Type: Grant
Filed: December 20, 2007
Date of Patent: September 28, 2010
Assignee: Sungkyunkwan University Foundation For Corporate Collaboration
Inventor: Hyun-Ju Park, So-Jung Park, Yang-Gyun Kim

METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS
Publication number: 20170096455
Abstract: The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.
Type: Application
Filed: March 20, 2015
Publication date: April 6, 2017
Applicant: The University of North Carolina at Chapel Hill
Inventor: Ralph Baric, Sudhakar Agnihothram, Boyd Yount

Canine coronavirus vaccine
Abstract: A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described.
Type: Grant
Filed: June 26, 2012
Date of Patent: December 1, 2015
Inventor: Nicola Decaro, Vito Martella, Gabriella Elia, Canio Buonavoglia

CANINE CORONAVIRUS VACCINE
Publication number: 20140205621
Abstract: A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described.
Type: Application
Filed: June 26, 2012
Publication date: July 24, 2014
Inventor: Nicola Decaro, Vito Martella, Gabriella Elia, Canio Buonavoglia

Compositions and methods for treating coronavirus infection
Abstract: The invention relates to the use of non-immunosuppressive cyclophilin inhibitors in the treatment of Coronavirus infection in a patient.
Type: Grant
Filed: May 8, 2015
Date of Patent: August 16, 2016
Assignee: Ludwig-Maximilians-Universitaet Muenchen
Inventor: Nikolai Naoumov, Albrecht von Brunn

Sensitive and Specific Test to Detect Sars Coronavirus
Publication number: 20070248949
Abstract: The invention provides a simple, specific and sensitive test for the presence of SARS coronavirus. Kits comprising primers useful in the test are also provided.
Type: Application
Filed: December 17, 2004
Publication date: October 25, 2007
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor: Masafumi Inoue, Wanjin Hong

Methods and compositions for chimeric coronavirus spike proteins
Abstract: The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.
Type: Grant
Filed: March 20, 2015
Date of Patent: February 6, 2018
Assignee: The University of North Carolina at Chapel Hill
Inventor: Ralph Baric, Sudhakar Agnihothram, Boyd Yount

CANINE RESPIRATORY CORONAVIRUS FOR TREATMENT AND PROTECTION AGAINST BACTERIAL INFECTIONS
Publication number: 20150157706
Abstract: Provided herein are compositions, combinations, and methods comprising Canine Respiratory Coronavirus (CRCoV), which are effective in treating or preventing respiratory infections associated secondary pathogens, such as Bordetella bronchiseptica, in animals.
Type: Application
Filed: May 24, 2013
Publication date: June 11, 2015
Inventor: Shelly Lynn Shields, Omar Yousif Abdelmagid

Immunogenic Composition for MERS Coronavirus Infection
Publication number: 20160296617
Abstract: Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.
Type: Application
Filed: February 28, 2014
Publication date: October 13, 2016
Inventor: Shibo Jiang, Lanying Du, Yusen Zhou, Guangyu Zhao

IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION
Publication number: 20190328865
Abstract: Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.
Type: Application
Filed: November 17, 2017
Publication date: October 31, 2019
Inventor: Lanying Du, Fang Li, Shibo Jiang, Yusen Zhou

Live attenuated Coronavirus vaccines
Publication number: 20060039926
Abstract: The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.
Type: Application
Filed: May 23, 2005
Publication date: February 23, 2006
Inventor: Mark Denison

Anti-coronavirus compounds
Publication number: 20060160866
Abstract: A method of treating coronavirus infection. The method includes administering to a subject suffering from or being at risk of suffering from such infection an effective amount of a compound of formula (I). Each variable in this formula is defined in the specification.
Type: Application
Filed: May 3, 2005
Publication date: July 20, 2006
Inventor: Chi-Huey Wong, Chung-Yi Wu, Jia-Tsrong Jan

Reagents and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus
Publication number: 20080044814
Abstract: This invention provides reagents and methods for detecting the severe acute respiratory syndrome coronavirus (SARS CoV). This invention also provides related compositions, kits, systems, and computers.
Type: Application
Filed: April 21, 2004
Publication date: February 21, 2008
Inventor: Ee Chee Ren, Martin L. Hibberd, Lisa Fong Poh Ng

Coronavirus, Nucleic Acid, Protein, and Methods for the Generation of Vaccine, Medicaments and Diagnostics
Publication number: 20110065091
Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.
Type: Application
Filed: July 26, 2010
Publication date: March 17, 2011
Inventor: Cornelia Maria Van Der Hoek

Compositions and methods for determining the presence of SARS coronavirus in a sample
Publication number: 20060134609
Abstract: The present invention relates to oligonucleotides useful for determining the presence of SARS coronavirus in a test sample. The oligonucleotides of the present invention may be incorporated into detection probes, capture probes and amplification oligonucleotides, or used in various combinations thereof.
Type: Application
Filed: April 16, 2004
Publication date: June 22, 2006
Inventor: Jeffrey Linnen, Daniel Kacian, Norman Nelson, Damon Getman, Sangeetha Vijaysri

Recombinant feline coronavirus S proteins
Publication number: 20040063093
Abstract: The present invention relates to polypeptides and proteins useful in the diagnosis and prevention of disease caused by feline infectious peritonitis virus (FIPV) and feline enteric coronavirus (FECV).
Type: Application
Filed: August 22, 2003
Publication date: April 1, 2004
Applicant: Pfizer, Inc.
Inventor: Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter, Elaine V. Jones

Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
Publication number: 20060024668
Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vacines, medicaments, nucleic acids and specific binding members.
Type: Application
Filed: August 18, 2004
Publication date: February 2, 2006
Inventor: Cornelia Hoek

Recombinant feline coronavirus S proteins
Publication number: 20020115064
Abstract: The present invention relates to polypeptides and proteins useful in the diagnosis and prevention of disease caused by feline infectious peritonitis virus (FIPV) and feline enteric coronavirus (FECV).
Type: Application
Filed: May 14, 2001
Publication date: August 22, 2002
Inventor: Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter, Elaine V. Jones

Immunogenic composition for MERS coronavirus infection
Abstract: Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.
Type: Grant
Filed: February 28, 2014
Date of Patent: February 13, 2018
Assignee: New York Blood Center, Inc.
Inventor: Shibo Jiang, Lanying Du, Yusen Zhou, Guangyu Zhao

Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars)
Publication number: 20060263765
Abstract: The present invention relates to novel peptides and mixtures thereof useful for detecting Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV) infections in humans and animals. Therefore, the present invention provides SARS-CoV diagnostic methods and kits.
Type: Application
Filed: May 5, 2004
Publication date: November 23, 2006
Inventor: Michel Houde, Jena-Michel Lacroix

Inhibitors of coronavirus protease and methods of use thereof
Publication number: 20050267071
Abstract: This invention provides organic boron-containing compounds, compositions thereof, and methods of using such compounds and compositions for inhibiting coronavirus protease(s) and for treating infections.
Type: Application
Filed: November 1, 2004
Publication date: December 1, 2005
Inventor: Ernesto Freire, Raphael Ottenbrite, Yingxin Xiao, Adrian Velazquez-Campoy, Stephanie Leavitt, Usman Bacha, Jennifer Barrila

Live attenuated coronavirus vaccines
Abstract: The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.
Type: Grant
Filed: May 23, 2005
Date of Patent: November 18, 2008
Assignee: Vanderbilt University
Inventor: Mark Denison

Epitope profiles of SARS coronavirus
Publication number: 20050106563
Abstract: The present invention relates to the identification of SARS corona virus epitopes specific to anti-SARS corona virus antibodies found in the sera of SARS patients. Epitope profiles can be used to detect and characterize SARS-CoV infection. The epitope polypeptides can also be used as immunogenic peptides to create polyclonal and/or monoclonal antibodies against SARS coronavirus.
Type: Application
Filed: September 8, 2004
Publication date: May 19, 2005
Inventor: Jen-Pin Huang, Lee-Hsuan Chen

CORONAVIRUS, NUCLEIC ACID, PROTEIN, AND METHODS FOR THE GENERATION OF VACCINE, MEDICAMENTS AND DIAGNOSTICS
Publication number: 20150050308
Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.
Type: Application
Filed: August 13, 2014
Publication date: February 19, 2015
Inventor: Cornelia Maria van der Hoek

Anti-coronavirus compounds
Abstract: A method of treating coronavirus infection. The method includes administering to a subject suffering from or being at risk of suffering from such infection an effective amount of a compound of formula (I). Each variable in this formula is defined in the specification.
Type: Grant
Filed: May 3, 2005
Date of Patent: July 9, 2013
Assignee: Academia Sinica
Inventor: Chi-Huey Wong, Chung-Yi Wu, Jia-Tsrong Jan

DNA encoding bovine coronavirus polypeptides E2 and E3
Abstract: Bovine coronavirus (BCV) E2 and E3 coding sequences and materials for producing the proteins E2 and E3 are provided. E2, E3, or antigenic fragments thereof are useful components for a BCV vaccine.
Type: Grant
Filed: July 27, 1992
Date of Patent: November 29, 1994
Assignee: Veterinary Infectious Disease Organization
Inventor: Michael D. Parker, Graham J. Cox, Lorne A. Babiuk

Detection of coronavirus infection
Publication number: 20060057161
Abstract: Isolated polypeptides containing one of SEQ ID NOs: 1-11. Also disclosed are (i) isolated nucleic acids encoding the polypeptides and related expression vectors and host cells; (ii) purified antibodies that recognize the polypeptides; and (iii) methods of producing the polypeptides, diagnosing infection with a coronavirus, and producing the antibodies.
Type: Application
Filed: September 16, 2004
Publication date: March 16, 2006
Inventor: Chang-Jen Huang, Yueh-Chun Hsieh, Chih-Ming Chou, Ho-Sheng Wu, Ting-Hsiang Lin

Protein Expression System Involving Mutated Severe Respiratory Syndrome-Associated Coronavirus 3C-Like Protease
Publication number: 20100203582
Abstract: A mutated severe acute respiratory syndrome-associated coronavirus 3C-like protease and use thereof for cleaving a protein that includes a cleavage site recognizable by the mutated protease to yield a polypeptide fragment of interest.
Type: Application
Filed: February 12, 2009
Publication date: August 12, 2010
Applicant: Academia Sinica
Inventor: Po-Huang Liang, Chih-Jung Kuo, Yan-Ping Shih

Recombinant feline coronavirus S proteins
Abstract: The present invention relates to polypeptides and proteins useful in the diagnosis and prevention of disease caused by feline infectious peritonitis virus (FIPV) and feline enteric coronavirus (FECV).
Type: Grant
Filed: May 14, 2001
Date of Patent: November 4, 2003
Assignee: Pfizer Inc.
Inventor: Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter, Elaine V. Jones

Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.
Type: Grant
Filed: August 13, 2014
Date of Patent: April 17, 2018
Assignee: AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.
Inventor: Cornelia Maria van der Hoek

Pathogenic porcine respiratory coronavirus
Abstract: The present invention provides a biologically pure culture of a novel pathogenic porcine respiratory coronavirus (PRCV) and a vaccine derived therefrom effective against PRCV infection and transmissible gastroenteritis virus (TGEV) infection.
Type: Grant
Filed: November 10, 1992
Date of Patent: May 30, 1995
Assignee: Iowa State University Research Foundation, Inc.
Inventor: Prem S. Paul, Eric M. Vaughn, Patrick G. Halbur

Sars coronavirus s proteins and uses thereof
Publication number: 20070116716
Abstract: The present invention relates to the use of a matured, glycosylated Spike (S) protein of SARS Coronavirus, fragments of the S protein, methods for producing the same, their use in detecting SARS infection, and their use or the use of their corresponding antibodies to treat patients suffering from SARS.
Type: Application
Filed: December 10, 2004
Publication date: May 24, 2007
Inventor: Shuo Shen, Wanjin Hong, Seng Lim, Yee Tan, Burtram Fielding, Phuay Goh, Timothy Tan, Jian Fu

TREATMENT OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
Publication number: 20170119859
Abstract: The present disclosure provides novel compositions and methods for treating an infection by Middle East respiratory syndrome coronavirus (MERS-CoV). In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by MERS:CoV.
Type: Application
Filed: May 29, 2015
Publication date: May 4, 2017
Inventor: Ronald D. MOSS

Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.
Type: Grant
Filed: July 26, 2010
Date of Patent: September 16, 2014
Assignee: Amsterdam Institute of Viral Genomics B.V.
Inventor: Cornelia Maria Van Der Hoek

Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vacines, medicaments, nucleic acids and specific binding members.
Type: Grant
Filed: August 18, 2004
Date of Patent: September 28, 2010
Assignee: Amsterdam Institute of Viral Genomics B.V.
Inventor: Cornelia van der Hoek

Multiplex RT-PCR/PCR for simultaneous detection of bovine coronavirus, bovine rotavirus, Cryptosporidium parvum, and Escherichia coli
Publication number: 20050239057
Abstract: The present invention provides a multiplex RT-PCR/PCR method, which enables in a single assay the simultaneous detection of any combination of bovine rotavirus, bovine coronavirus, Cryptosporidium parvum, and optionally, Escherichia coli strains producing K99 pili or heat-stable enterotoxin STa.
Type: Application
Filed: January 5, 2005
Publication date: October 27, 2005
Applicant: Board of Trustees of Michigan State University
Inventor: Roger Maes, Annabel Wise

USE OF TAURINE IN PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY VIRUSES OF GENUS CORONAVIRUS AND/OR GENUS ROTAVIRUS
Publication number: 20170368006
Abstract: The present invention provides use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus, for example, porcine epidemic diarrhea, porcine transmissible gastroenteritis, rotavirus diarrhea and the like.
Type: Application
Filed: January 17, 2015
Publication date: December 28, 2017
Inventor: Yongdong WANG, Jiyuan CAO, Shifa ZHU, Wen CHENG, Zhipeng HUANG

Oligonucleotides, reagents and amplification methods for detecting severe acute respiratory syndrome coronavirus
Abstract: This invention provides oligonucleotides, reagents and amplification methods for detecting the severe acute respiratory syndrome coronavirus (SARS CoV). This invention also provides related compositions, kits, systems, and computers.
Type: Grant
Filed: April 21, 2004
Date of Patent: May 5, 2009
Assignee: Genome Institute of Singapore
Inventor: Ee Chee Ren, Martin L. Hibberd, Lisa Fong Poh Ng

MULTIPLEX RT-PCR/PCR FOR SIMULTANEOUS DETECTION OF BOVINE CORONAVIRUS, BOVINE ROTAVIRUS, CRYPTOSPORIDIUM PARVUM, AND ESCHERICHIA COLI
Publication number: 20050026144
Abstract: The present invention provides a multiplex RT-PCR/PCR method, which enables in a single assay the simultaneous detection of any combination of bovine rotavirus, bovine coronavirus, Cryptosporidium parvum, and optionally, Escherichia coli strains producing K99 pili or heat-stable enterotoxin STa.
Type: Application
Filed: February 20, 2001
Publication date: February 3, 2005
Applicant: Board of Trustees operating Michigan State University
Inventor: Roger Maes, Annabel Wise

Vaccine based on TGEV for protection of canines against canine coronavirus
Abstract: A method for preventing canine coronavirus in dogs is disclosed which comprises administering to a dog a live or inactivated vaccine prepared from transmissible gastroenteritis virus of swine (a TGEV vaccine). An inactivated vaccine composition for use in such a method and a process for the manufacture of the inactivated vaccine composition are described.
Type: Grant
Filed: March 30, 1999
Date of Patent: June 13, 2000
Assignee: Pfizer, Inc.
Inventor: Dale Bordt, Hans Draayer

Vaccine based on TGEV for protection of dogs against canine coronavirus
Abstract: A method for preventing canine coronavirus in dogs is disclosed which comprises administering to a dog a live or inactivated vaccine prepared from transmissible gastroenteritis virus of swine (a TGEV vaccine). An inactivated vaccine composition for use in such a method and a process for the manufacture of the inactivated vaccine composition are described.
Type: Grant
Filed: March 27, 1991
Date of Patent: June 15, 1999
Assignee: Pfizer, Inc.
Inventor: Dale Bordt, Hans Draayer

Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
Abstract: The present invention provides use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus, for example, porcine epidemic diarrhea, porcine transmissible gastroenteritis, rotavirus diarrhea and the like.
Type: Grant
Filed: January 17, 2015
Date of Patent: June 11, 2019
Inventor: Yongdong Wang, Jiyuan Cao, Shifa Zhu, Wen Cheng, Zhipeng Huang

Protein expression system involving mutated severe respiratory syndrome-associated coronavirus 3C-like protease
Abstract: A mutated severe acute respiratory syndrome-associated coronavirus 3C-like protease and use thereof for cleaving a protein that includes a cleavage site recognizable by the mutated protease to yield a polypeptide fragment of interest.
Type: Grant
Filed: February 12, 2009
Date of Patent: November 8, 2011
Assignee: Academia Sinica, Taiwan
Inventor: Po-Huang Liang, Chih-Jung Kuo, Yan-Ping Shih

Feline infectious peritonitis (FIP) and systemic multi-organ coronavirus biomarkers and screening methods
Publication number: 20060051744
Abstract: Methods for screening for FIP infection or other multi-organ coronaviruses are disclosed, as well as isolated antibodies and kits useful for performing such methods. Biomarkers for multi-organ coronavirus infections include soluble enolase; antibodies to enolase; and circulating immune complexes that contain enolase. The methods find application in diagnosis, treatment, vaccine-development, and selection or breeding for disease-resistance.
Type: Application
Filed: June 28, 2005
Publication date: March 9, 2006
Inventor: Kimberly Austin, Sanjay Kapil, Jeong-Ki Kim

CYTOTOXIC T CELL EPITOPE PEPTIDE FOR SARS CORONAVIRUS, AND USE THEREOF
Publication number: 20110262529
Abstract: The present invention aims to provide a novel CTL epitope peptide of the SARS coronavirus. The present invention provides a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12, 13, 15, 17, 18, 23 and 24.
Type: Application
Filed: November 27, 2009
Publication date: October 27, 2011
Inventor: Masanori Matsui, Tetsuya Uchida, Hiroshi Oda

HUMAN MONOCLONAL ANTIBODIES AGAINST THE MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-COV) AND ENGINEERED BISPECIFIC FUSIONS WITH INHIBITORY PEPTIDES
Publication number: 20160264647
Abstract: The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.
Type: Application
Filed: October 16, 2014
Publication date: September 15, 2016
Inventor: Dimiter S. Dimitrov, Tianlei Ying, Tina W. Ju, Kwok Yung Yuen

Angiotensin-converting enzyme-2 as a receptor for the SARS coronavirus
Publication number: 20050282154
Abstract: The present invention is based upon the identification of human angiotensin-converting enzyme-2 (ACE-2) as a functional receptor for the SARS coronavirus. Transfection of cells with ACE-2 confers upon them the ability to support viral replication. In addition, assays performed using ACE-2 together with the S protein of the SARS virus or a fragment derived from the S protein can be used to identify inhibitors that block the interaction between virus and host cell.
Type: Application
Filed: October 5, 2004
Publication date: December 22, 2005
Inventor: Michael Farzan, Wenhui Li, Michael Moore

PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING DISEASE CAUSED BY CORONAVIRUS AND/OR ROTAVIRUS
Publication number: 20180008563
Abstract: The present invention provides a pharmaceutical composition for prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus. The pharmaceutical composition includes the following components by weight percent: 0.5-100% of taurine, 0-85% of a vitamin complex, and 0-15% of a flavoring agent.
Type: Application
Filed: January 17, 2015
Publication date: January 11, 2018
Inventor: Yongdong WANG, Jiyuan CAO, Shifa ZHU, Wen CHENG, Zhipeng HUANG

DNA encoding the Canine coronavirus spike protein
Abstract: The invention is related to a nucleic acid sequence &coding a Canine coronavirus (CCV) spike protein. Such a protein can be used for the immunization of dogs against CCV infection. The nucleic acid sequence encoding the CCV spike protein can be applied for the preparation of the spike protein by means of genetic engineering techniques or can be applied for the preparation of vector vaccines.
Type: Grant
Filed: September 19, 1994
Date of Patent: August 26, 1997
Assignee: Akzo Nobel N.V.
Inventor: Thomas David Kay Brown, Brian Colin Horsburgh

Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)
Publication number: 20040229219
Abstract: The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus.
Type: Application
Filed: April 29, 2004
Publication date: November 18, 2004
Inventor: William R. Gallaher, Robert F. Garry

Multiplex RT-PCR/PCR for simultaneous detection of bovine coronavirus, bovine rotavirus, Cryptosporidium parvum, and Escherichia coli
Abstract: The present invention provides a multiplex RT-PCR/PCR method, which enables in a single assay the simultaneous detection of any combination of bovine rotavirus, bovine coronavirus, Cryptosporidium parvum, and optionally, Escherichia coli strains producing K99 pili or heat-stable enterotoxin STa.
Type: Grant
Filed: February 20, 2001
Date of Patent: March 15, 2005
Assignee: Board of Trustees of Michigan State University
Inventor: Roger K. Maes, Annabel G. Wise

Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof
Abstract: The present invention aims to provide a novel CTL epitope peptide of the SARS coronavirus. The present invention provides a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12, 13, 15, 17, 18, 23 and 24.
Type: Grant
Filed: November 27, 2009
Date of Patent: September 9, 2014
Inventor: Masanori Matsui, Tetsuya Uchida, Hiroshi Oda

Proteins encoded by the severe acute respiratory syndrome (SARS) coronavirus and a role in apoptosis
Publication number: 20060292178
Abstract: Compositions related to expressed severe acute respiratory syndrome (SARS) coronavirus group-specific polypeptides are provided. Further provided are methods and compositions related to the use of these polypeptides, in particular use for inducing apoptosis in cells, diagnosing SARS infection and screening for modulator and inhibitor compounds of such polypeptides and in turn the virus itself, and in the treatment and/or prophylaxis of disease caused by SARS infection.
Type: Application
Filed: August 4, 2005
Publication date: December 28, 2006
Applicant: Agency for Science, Technology and Research
Inventor: Wanjin Hong, Seng Lim, Yee Tan, Burtram Fielding, Shuo Shen, Hoe Peng Tan

RNAI Agents For Anti-SARS Coronavirus Therapy
Publication number: 20070203082
Abstract: The present invention provides compositions and methods that are useful for the treatment of severe acute respiratory syndrome (SARS). More specifically, nucleic acid agents such as siRNA molecules and their analogues that target respiratory infections including SARS coronavirus and their methods of use are described, for clinical treatments of SARS, respiratory viral infections, for prevention and treatment of respiratory infections as needed for bio-defense, for treatment of respiratory diseases, and for discovery of therapeutic targets for respiratory diseases and infections.
Type: Application
Filed: April 26, 2004
Publication date: August 30, 2007
Applicant: Intradigm Corporation
Inventor: Quinn Tang, Patrick Lu, Frank Xie, Yija Liu, Jun Xu, Martin Woodle

Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
Publication number: 20060240551
Abstract: The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.
Type: Application
Filed: February 8, 2006
Publication date: October 26, 2006
Inventor: Shibo Jiang, Yuxian He

Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
Abstract: The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.
Type: Grant
Filed: October 16, 2014
Date of Patent: September 24, 2019
Inventor: Dimiter S. Dimitrov, Tianlei Ying, Tina W. Ju, Kwok Yung Yuen

Use Of Proteins And Peptides Encoded By The Genome Of A Novel Sars-Associated Coronavirus Strain
Publication number: 20070275002
Abstract: The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents and as a vaccine.
Type: Application
Filed: December 2, 2004
Publication date: November 29, 2007
Inventor: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederick Kunst, Jean-Michel Betton, Sylvie Gerbaud, Ana Burguiere, Saliha Azebi, Pierre Charneua, Frederic Tangy, Chantal Combredet, Jean-Francois Delagneau, Monique Martin

Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
Publication number: 20060110758
Abstract: The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR.
Type: Application
Filed: October 28, 2005
Publication date: May 25, 2006
Inventor: Bojian Zheng, Yi Guan, Jiandong Huang, Ming-Liang He

Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
Abstract: The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.
Type: Grant
Filed: February 8, 2006
Date of Patent: December 8, 2009
Assignee: New York Blood Center, Inc.
Inventor: Shibo Jiang, Yuxian He

Recombinant feline coronavirus S proteins
Abstract: The present invention provides polynucleotide molecules encoding portions of the S protein from feline infectious peritonitis virus (FIPV). The present invention further provides polynucleotide molecules encoding the entire S protein or portions thereof from feline enteric coronavirus (FECV). The polynucleotide molecules of the present invention are useful as diagnostic reagents.
Type: Grant
Filed: February 22, 1995
Date of Patent: August 28, 2001
Assignee: Pfizer Inc
Inventor: Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter, Elaine V. Jones

Novel strain of sars-associated coronavirus and applications thereof
Publication number: 20070128224
Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.
Type: Application
Filed: December 2, 2004
Publication date: June 7, 2007
Inventor: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederick Kunst, Benoit Callendret, Jean-Michel Betton, Valerie Lorin, Sylvie Gerbaud, Ana Burguiere, Saliha Azebi, Pierre Charneau, Frederic Tangy, Chantal Combredet, Jean-Francois Delagneau, Monique Martin

Crystal structure of human coronavirus 229E main proteinase and uses for developing SARS inhibitors
Publication number: 20090137818
Abstract: The invention relates to a method of developing a main proteinase SARS inhibitor. Human coronaviruses are major causes of upper respiratory tract illnesses in humans, in particular, the common cold. Recent investigations have shown that a novel coronavirus causes the Severe Acute Respiratory Syndrome (SARS), a disease that is characterized by high fever, malaise, rigor, headache, non-productive cough or dyspnea, which is rapidly spreading. Within the scope of the invention, based on the structural analysis of the binding mode of the SARS Mpro enzyme, a group of prototype inhibitors is provided that acts as suitable drugs targeting a majority of viral infections of the respiratory tract, including SARS.
Type: Application
Filed: November 10, 2005
Publication date: May 28, 2009
Inventor: Rolf Hilgenfeld, Kanchan Anand, John Ziebuhr, Jeroen R. Mesters, Parvesh Wadhwani

USE OF PROTEINS AND PEPTIDES ENCODED BY THE GENOME OF A NOVEL SARS-ASSOCIATED CORONAVIRUS STRAIN
Publication number: 20120082693
Abstract: The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents and as a vaccine.
Type: Application
Filed: July 20, 2011
Publication date: April 5, 2012
Inventor: Sylvie VAN DER WERF, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin

Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
Publication number: 20150337029
Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
Type: Application
Filed: May 20, 2015
Publication date: November 26, 2015
Inventor: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam

Severe acute respiratory syndrome coronavirus
Publication number: 20060257852
Abstract: An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.
Type: Application
Filed: April 9, 2004
Publication date: November 16, 2006
Applicant: Chiron Corporation
Inventor: Rino Rappuoli, Vega Masignani, Konrad Stadler, Jens Gregersen, David Chien, Jang Han, John Polo, Amy Weiner, Michael Houghton, Hyun Song, Mi-Young Seo, John Donnelly, Hans Klenk, Nicholas Valiante

Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
Publication number: 20190351049
Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
Type: Application
Filed: August 2, 2019
Publication date: November 21, 2019
Inventor: Christos KYRATSOUS, Neil STAHL, Sumathi SIVAPALASINGAM

Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
Abstract: The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR.
Type: Grant
Filed: October 28, 2005
Date of Patent: February 17, 2009
Assignee: The University of Hong Knog
Inventor: Bojian Zheng, Yi Guan, Jiandong Huang, Ming-Liang He

Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
Publication number: 20170340728
Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
Type: Application
Filed: June 26, 2017
Publication date: November 30, 2017
Inventor: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam

NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF
Publication number: 20110065089
Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.
Type: Application
Filed: April 6, 2010
Publication date: March 17, 2011
Inventor: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE
Publication number: 20190256579
Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
Type: Application
Filed: May 3, 2019
Publication date: August 22, 2019
Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventor: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola

Crystal structure of human coronavirus 229E main proteinase and uses for developing SARS inhibitors
Abstract: The invention relates to a method of developing a main proteinase SARS inhibitor. Human coronaviruses are major causes of upper respiratory tract illnesses in humans, in particular, the common cold. Recent investigations have shown that a novel coronavirus causes the Severe Acute Respiratory Syndrome (SARS), a disease that is characterized by high fever, malaise, rigor, headache, non-productive cough or dyspnea, which is rapidly spreading. Within the scope of the invention, based on the structural analysis of the binding mode of the SARS Mpro enzyme, a group of prototype inhibitors is provided that acts as suitable drugs targeting a majority of viral infections of the respiratory tract, including SARS.
Type: Grant
Filed: November 10, 2005
Date of Patent: June 7, 2011
Assignee: Universitat zu Luebeck
Inventor: Rolf Hilgenfeld, Kanchan Anand, John Ziebuhr, Jeroen R. Mesters, Parvesh Wadhwani

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE
Publication number: 20180244756
Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
Type: Application
Filed: February 24, 2016
Publication date: August 30, 2018
Applicant: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
Inventor: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola

TREATMENT OF CORONAVIRUS INFECTION
Publication number: 20090149545
Abstract: A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1, bepridil, cinnarizine, ethisterone, pararosaniline, methylbenzethonium, niclosamide, pipobroman, homidium, calcimycin, anisomycin, metergoline, amodiaquine, danazol, danthron, ethopropazine, eucatropine, nortriptyline, resorcinol, mebhydrolin, mebeverine, trimipramine, triflupromazine, chlorprothixene, cyclobenzaprine, enoxacin, sulfanitran, monensin, nigericin, perphenazine, methoxamine, astemizole, trifluoperazine, acriflavinium, rotenone, acebutolol, quabain, methiothepin, convallatoxin, halcinonide, cyclosporin, pimethixene, mycophenolic acid, promethazine, mesoridazine,
Type: Application
Filed: May 28, 2004
Publication date: June 11, 2009
Inventor: Tsu-An Hsu, Hsing-Pang Hsieh, Yu-Sheng Chao, Chi-Min Chen, Jia-Tsrong Jan, Hwan-Wun Liu

Strain of SARS-associated coronavirus and applications thereof
Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.
Type: Grant
Filed: December 2, 2004
Date of Patent: June 15, 2010
Inventor: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederick Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin

Strain of SARS-associated coronavirus and applications thereof
Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.
Type: Grant
Filed: April 6, 2010
Date of Patent: January 1, 2013
Inventor: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin

Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
Type: Grant
Filed: February 24, 2016
Date of Patent: May 28, 2019
Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventor: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola

Treatment of coronavirus infection
Abstract: A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1, bepridil, cinnarizine, ethisterone, pararosaniline, methylbenzethonium, niclosamide, pipobroman, homidium, calcimycin, anisomycin, metergoline, amodiaquine, danazol, danthron, ethopropazine, eucatropine, nortriptyline, resorcinol, mebhydrolin, mebeverine, trimipramine, triflupromazine, chlorprothixene, cyclobenzaprine, enoxacin, sulfanitran, monensin, nigericin, perphenazine, methoxamine, astemizole, trifluoperazine, acriflavinium, rotenone, acebutolol, quabain, methiothepin, convallatoxin, halcinonide, cyclosporin, pimethixene, mycophenolic acid, promethazine, mesoridazine,
Type: Grant
Filed: May 28, 2004
Date of Patent: June 9, 2009
Assignee: National Health Research Insitutes
Inventor: Tsu-An Hsu, Hsing-Pang Hsieh, Yu-Sheng Chao, Chi-Min Chen, Jia-Tsrong Jan, Hwan-Wun Liu

Coronavirus isolated from humans
Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.
Type: Grant
Filed: April 12, 2004
Date of Patent: May 22, 2007
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
Inventor: Paul A. Rota, Larry J. Anderson, William J. Bellini, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Suxiang Tong, Sherif R. Zaki

Methods for producing recombinant coronavirus
Publication number: 20040235132
Abstract: A helper cell for producing an infectious, replication defective, coronavirus (or more generally nidovirus) particle cell comprises (a) a nidovirus permissive cell; (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein; and (c) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon.
Type: Application
Filed: May 25, 2004
Publication date: November 25, 2004
Inventor: Kristopher M. Curtis, Boyd Yount, Ralph S. Baric

Bacterial artificial chromosome construct encoding recombinant coronavirus
Abstract: The present invention relates to methods of preparing a DNA comprising steps, wherein (a) a DNA comprising a full length copy of the genomic RNA (gRNA) or an RNA virus; or (b) a DNA comprising one or several fragments of a gRNA of an RNA virus, which fragments code for an RNA dependent RNA polymerase and at least one structural or non-structural protein; or (c) a DNA having a homology of at least 60% to the sequences of (a) or (b); is cloned into a bacterial artificial chromosome (BAC). Additionally, DNAs are provided, which comprise sequences derived from the genomic RNA (gRNA) of a coronavirus which sequences have a homology of at least 60% to the natural sequence of the virus and code for an RNA dependent RNA polymerase and at least one structural or no-structural protein, wherein a fragment of said DNA is capable of being transcribed into RNA which RNA can be assembled to a virion.
Type: Grant
Filed: November 30, 2000
Date of Patent: November 4, 2008
Assignee: Consejo Superior de Investigationes Cientificas
Inventor: Luis Enjuanes Sanchez

Methods for producing recombinant coronavirus
Abstract: A helper cell for producing an infectious, replication defective, coronavirus (or more generally nidovirus) particle cell comprises (a) a nidovirus permissive cell; (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein; and (c) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon.
Type: Grant
Filed: April 19, 2002
Date of Patent: October 9, 2007
Assignee: The University of North Carolina at Chapel Hill
Inventor: Kristopher M. Curtis, Boyd Yount, Ralph S. Baric

Coronavirus isolated from humans
Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.
Type: Grant
Filed: May 14, 2007
Date of Patent: August 17, 2010
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
Inventor: Paul A. Rota, Larry J. Anderson, William J. Bellini, Michael D. Bowen, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Byron T. Cook, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Jeanette Guarner, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Richard F. Meyer, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Christopher D. Paddock, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Wun-Ju Shieh, Suxiang Tong, Sherif R. Zaki

Nucleocapsid-independent specific viral RNA packaging and uses thereof
Publication number: 20040175829
Abstract: The present invention shows that expressed coronavirus envelope protein M specifically interacted with co-expressed non-coronavirus RNA transcripts containing the short viral packaging signal in the absence of coronavirus N protein. Furthermore, this M protein-packaging signal interaction led to specific packaging of the packaging-signal-containing RNA transcripts into coronavirus-like particles in the absence of N protein. These findings highlight a novel RNA packaging mechanism for an enveloped virus, and a novel coronavirus-based expression system can be developed based on the data presented herein.
Type: Application
Filed: March 5, 2004
Publication date: September 9, 2004
Inventor: Shinji Makino, Krishna Narayanan

METHODS AND COMPOSITIONS IN THE TREATMENT OF CORONAVIRUSES
Publication number: 20110190273
Abstract: The invention relates generally to the field of virology, and relates to the identification and characterization of the targets involved in the evasion strategy of viruses and to the use thereof in methods to identify anti-viral compounds. More in particular to identify compounds which are modulators of myosin light chain kinase (MLCK), a target within said entry and immune-evasion strategy.
Type: Application
Filed: May 29, 2009
Publication date: August 4, 2011
Applicant: UNIVERSITEIT GENT
Inventor: Hannah Dewerchin, Hans Nauwynck

Adjuvants for vaccines
Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed.
Type: Grant
Filed: March 24, 1988
Date of Patent: September 10, 1991
Assignee: American Home Products Corporation
Inventor: William M. Acree, Bobby Edwards, John W. Black

Methods for reducing the internalization of viruses and identification of compounds effective thereof
Abstract: The invention relates generally to the field of virology, and relates to the identification and characterization of the targets involved in the evasion strategy of viruses and to the use thereof in methods to identify anti-viral compounds. More in particular to identify compounds which are modulators of myosin light chain kinase (MLCK), a target within said entry and immune-evasion strategy.
Type: Grant
Filed: May 29, 2009
Date of Patent: October 23, 2012
Assignee: Universiteit Gent
Inventor: Hannah Dewerchin, Hans Nauwynck

ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES
Publication number: 20060258577
Abstract: The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infection, in a subject, such as a human subject.
Type: Application
Filed: April 28, 2004
Publication date: November 16, 2006
Inventor: John Erickson, Abelardo Silva

Compositions of coronaviruses with a recombination-resistant genome
Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.
Type: Grant
Filed: January 19, 2006
Date of Patent: November 17, 2009
Assignee: The University of North Carolina at Chapel Hill
Inventor: Ralph S. Baric, Rhonda Roberts, Boyd Yount, Kristopher M. Curtis

ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES
Publication number: 20070185027
Abstract: The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infaction, in a subject, such as a human subject.
Type: Application
Filed: November 9, 2006
Publication date: August 9, 2007
Applicant: SEQUOIA PHARMACEUTICALS, INC.
Inventor: John Erickson, Abelardo Silva

Chimaeric Protein
Publication number: 20120177675
Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.
Type: Application
Filed: July 5, 2010
Publication date: July 12, 2012
Applicant: INSTITUTE FOR ANIMAL HEALTH
Inventor: Paul Britton, Erica Bickerton, Maria Armesto

Compositions and methods for detecting a non plus-stranded RNA virus
Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
Type: Grant
Filed: November 3, 2004
Date of Patent: December 7, 2010
Assignee: Diagnostic Hybrids, Inc.
Inventor: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth

Antiviral agents for the treatment, control and prevention of infections by coronaviruses
Abstract: The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infection, in a subject, such as a human subject.
Type: Grant
Filed: April 28, 2004
Date of Patent: December 19, 2006
Assignee: Sequoia Pharmaceuticals, Inc.
Inventor: John W. Erickson, Abelardo Silva

Chimaeric protein
Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.
Type: Grant
Filed: July 5, 2010
Date of Patent: September 9, 2014
Assignee: The Pirbright Institute
Inventor: Paul Britton, Erica Bickerton, Maria Armesto

Antibodies against SARS-CoV and methods of use thereof
Publication number: 20050249739
Abstract: The invention provides scFv antibodies and monoclonal antibodies that neutralize SARS-CoV. Also provided are methods of treating and/or preventing a coronavirus-related disease or disorder such as SARS. The invention also provides methods of vaccinating a patient against SARS-CoV. Also provided are methods of diagnosing coronavirus-related diseases or disorders and methods of detecting the presence of a coronavirus in a sample. The invention additionally provides methods of screening for compounds that modulate the binding of SARS-CoV and the SARS-CoV receptor ACE2 as well as for compounds useful to treat SARS-CoV-related diseases or disorders.
Type: Application
Filed: November 24, 2004
Publication date: November 10, 2005
Inventor: Wayne Marasco, Jianhua Sui

MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONOVIRUSES
Publication number: 20190062785
Abstract: The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.
Type: Application
Filed: March 31, 2017
Publication date: February 28, 2019
Inventor: Reed F. Johnson, Matthias Schnell, Lisa E. Hensley, Christoph Wirblich, Christopher M. Coleman, Matthew B. Frieman

Use of hab18g/cd147 molecule as target for antiviral antagonists and thus obtained antiviral antagonist
Publication number: 20070003565
Abstract: The present invention relates to use of HAb18G/CD147 molecule as target for designing antiviral antagonist and the antiviral antagonist designed by using such molecule, especially antagonist against SARS Coronavirus and AIDS virus HIV-1. Antagonist of the present invention includes antibody, polypeptide, immune complex, derivative, small molecule compound and so on, which is able to prevent SARS Coronavirus and AIDS virus (HIV-1) from invading host cell, thereby exerts its antagonistic antiviral effect. It is provided by in vitro experiment that such antagonist has inhibitory effect against SARS Coronavirus and AIDS virus (HIV-1), thus is potential antiviral candidate drug.
Type: Application
Filed: June 9, 2003
Publication date: January 4, 2007
Inventor: Zhinan Chen

Cell surface expression vector of sars virus antigen and microorganisms transformed thereby
Publication number: 20060140971
Abstract: The present invention relates to a surface expression vector of SARS coronavirus antigen containing a gene encoding an antigen of SARS inducing coronavirus and any one or two or more of genes pgsB, pgsC and pgsA encoding poly-gamma-glutamic acid synthase complex, a microorganism transformed by the surface expression vector, and a SARS vaccine comprising the microorganism. According to the present invention, it is possible to economically produce a vaccine for prevention and treatment of SARS using a recombinant strain expressing an SARS coronavirus antigen on their surface.
Type: Application
Filed: June 4, 2004
Publication date: June 29, 2006
Inventor: Moon-Hee Sung, Chul-Joong Kim, Chang-Min Jung, Seung-Pyo Hong, Jong Su Lee, Jae Choi, Kwang Kim, Kuroda Shunichi, Ha Ryoung Poo

Antibodies against SARS-CoV and methods of use thereof
Abstract: The invention provides scFv antibodies and monoclonal antibodies that neutralize SARS-CoV. Also provided are methods of treating and/or preventing a coronavirus-related disease or disorder such as SARS. The invention also provides methods of vaccinating a patient against SARS-CoV. Also provided are methods of diagnosing coronavirus-related diseases or disorders and methods of detecting the presence of a coronavirus in a sample. The invention additionally provides methods of screening for compounds that modulate the binding of SARS-CoV and the SARS-CoV receptor ACE2 as well as for compounds useful to treat SARS-CoV-related diseases or disorders.
Type: Grant
Filed: November 24, 2004
Date of Patent: July 6, 2010
Assignee: Dana Farber Cancer Institute, Inc.
Inventor: Wayne Marasco, Jianhua Sui

Attenuated Infectious Bronchitis Virus
Publication number: 20190022214
Abstract: The present invention provides a live, attenuated coronavirus comprising a mutation in non-structural protein nsp-3 and/or deletion of accessory proteins 3a and 3b. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
Type: Application
Filed: January 26, 2017
Publication date: January 24, 2019
Inventor: Erica Bickerton, Sarah Keep, Paul Britton

Inhibitors of SARS 3C like protease
Publication number: 20060014821
Abstract: The invention relates to methods of inhibiting SARS-related coronavirus viral replication activity comprising contacting a SARS-related coronavirus protease with a therapeutically effective amount of a SARS 3C like protease inhibitor, and compositions comprising the same.
Type: Application
Filed: August 13, 2004
Publication date: January 19, 2006
Inventor: Mingying He, Robert Kania, Jihong Lou, Simon Planken

Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof
Publication number: 20050112554
Abstract: Severe Acute Respiratory Syndrome (“SARS”) is a human respiratory disease of recent origin, widespread infectivity, recurring incidence, and significant mortality. Although there is abundant evidence suggesting that the coronavirus responsible for the disease (“SARS-CoV”) evolves during an outbreak, there is currently little data on the earliest strains of this coronavirus. The present invention is directed to the characterization of the genomic RNA sequences of these earliest SARS coronaviruses, to the identification of nucleotide positions within the SARS-CoV genomic RNA that are characteristic of the different evolutionary stages of the coronavirus, to kits based on these positions for use in diagnosis of the disease in patients, and for the development of vaccines to the disease based on the lowered virulence and contagiousness of these earliest strains of SARS-CoV.
Type: Application
Filed: July 9, 2004
Publication date: May 26, 2005
Inventor: Guoping Zhao, Rui Heng Xu, Xinwei Wu, Changchun Tu, Huai-Dong Song, Yixue Li, Jinlin Hou, Jun Xu, Jun Min

Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
Publication number: 20040235952
Abstract: The invention relates to methods of inhibiting SARS-related coronavirus viral replication activity comprising contacting a SARS-related coronavirus protease with a therapeutically effective amount of a rhinovirus protease inhibitor, and compositions comprising the same.
Type: Application
Filed: April 27, 2004
Publication date: November 25, 2004
Applicant: Agouron Pharmaceuticals, Inc.
Inventor: Shella Fuhrman, David A. Matthews, Amy Karen Patick, Paul Rejto

Recombinant virus and use thereof
Publication number: 20090214587
Abstract: The present invention provides a recombinant virus which is efficacious and highly safe in preventing the onset of SARS infection and a vaccine for SARS coronavirus containing the same. The recombinant virus of the invention can express a SARS coronavirus gene.
Type: Application
Filed: October 11, 2005
Publication date: August 27, 2009
Inventor: Michinori Kohara, Kyosuke Mizuno, Hisatoshi Shida, Kouji Matsushima, Koichi Morita, Minoru Kidokoro, Yukie Sameshima

Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof
Abstract: Severe Acute Respiratory Syndrome (“SARS”) is a human respiratory disease of recent origin, widespread infectivity, recurring incidence, and significant mortality. Although there is abundant evidence suggesting that the coronavirus responsible for the disease (“SARS-CoV”) evolves during an outbreak, there is currently little data on the earliest strains of this coronavirus. The present invention is directed to the characterization of the genomic RNA sequences of these earliest SARS coronaviruses, to the identification of nucleotide positions within the SARS-CoV genomic RNA that are characteristic of the different evolutionary stages of the coronavirus, to kits based on these positions for use in diagnosis of the disease in patients, and for the development of vaccines to the disease based on the lowered virulence and contagiousness of these earliest strains of SARS-CoV.
Type: Grant
Filed: July 9, 2004
Date of Patent: January 22, 2008
Assignee: Chinese National Human Genome Center at Shanghai
Inventor: Guoping Zhao, Rui Heng Xu, Xinwei Wu, Changchun Tu, Huai-Dong Song, Yixue Li, Jinlin Hou, Jun Xu, Jun Min

PCR PRIMER SET FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR DETECTING SARS-CORONAVIRUS USING THE SAME
Publication number: 20080096186
Abstract: Provided are SARS-CoV detection PCR primers having nucleotide sequences as set forth in SEQ ID NOS: 1-46, a method for detecting SARS-CoV using the primers, and a SARS-CoV detection kit including the primers.
Type: Application
Filed: November 24, 2004
Publication date: April 24, 2008
Inventor: Hee-kyun Lim, Sang-hyo Kim, Jung-joo Hwang, Young-sun Lee, Young-a Kim

Propagation of bovine cononavirus in chinese hamster ovary cells
Abstract: The present invention provides methods for using Chinese hamster ovary (CHO) cells for the anchorage-dependent and suspension-culture propagation of coronaviruses, including bovine coronavirus. In one embodiment, bovine coronavirus VR874 is cultured in CHO-K1 cells under conditions in which the virus proliferates.
Type: Grant
Filed: January 25, 2000
Date of Patent: February 4, 2003
Assignee: Schering-Plough Veterinary Corporation
Inventor: Michael J. Francis

PCR PRIMER SET DETECTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR DETECTING SARS-CORONAVIRUS USING THE SAME
Publication number: 20080194422
Abstract: Provided are SARS-CoV detection PCR primers having nucleotide sequences as set forth in SEQ ID NOS: 1-46, a method for detecting SARS-CoV using the primers, and a SARS-CoV detection kit including the primers.
Type: Application
Filed: April 21, 2008
Publication date: August 14, 2008
Applicant: SAMSUNG ELECTRONICS CO., LTD.
Inventor: Hee-kyun LIM, Sang-hyo KIM, Jung-joo HWANG, Young-sun LEE, Young-a KIM

Transgenic Mouse Lines Expressing Human Ace2 and Uses Thereof
Publication number: 20090083865
Abstract: Animal models for severe acute respiratory syndrome-coronavirus infection of humans are needed to elucidate SARS pathogenesis and develop vaccines and antivirals. Transgenic mice were developed expressing human angiotensin-converting enzyme 2, a functional receptor for the virus, under the regulation of a global promoter. A transgenic lineage, designated AC70, was among the best characterized against SARS coronavirus infection, showing weight loss and other clinical manifestations before reaching 100% mortality within 8 days after intranasal infection. Inflammatory mediators were also detected in these tissues, coinciding with high levels of virus replication. In contrast, infected transgene-negative mice survived without showing any clinical illness.
Type: Application
Filed: January 11, 2007
Publication date: March 26, 2009
Inventor: Teh-Sheng Chan, Shinji Makino, Clarence J. Peters, Chien-Te K. Tseng

PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF
Publication number: 20080300191
Abstract: Disclosed are protease inhibitors for coronaviruses and SARS-CoV, or picornaviruses, and the use of these protease inhibitors for preventing, reducing, ameliorating and treating a disease or condition caused by coronaviruses and SARS-CoV, or picornaviruses.
Type: Application
Filed: May 6, 2004
Publication date: December 4, 2008
Inventor: Sui Xiong Cai, William E. Kemnitzer, Hong Zhang, Han-Zhong Zhang

VIRAL PROTEIN
Publication number: 20090068636
Abstract: The present invention is directed to an isolated polypeptide containing SEQ ID NO: 1 or an immunogenic fragment thereof. Also disclosed is an isolated nucleic acid encoding the polypeptide or containing a sequence at least 70% identical to SEQ ID NO: 3. Within the scope of this invention are related expression vectors, host cells, and antibodies. Also disclosed are methods of producing the polypeptide, diagnosing coronavirus infection, and identifying a test compound for treating coronavirus infection.
Type: Application
Filed: September 19, 2007
Publication date: March 12, 2009
Inventor: Fang-Jen Lee, Chia-Jung Yu, Ming-Fu Chang, Hong-Nerng Ho

Preventive or therapeutic composition for viral infectious disease
Publication number: 20060189542
Abstract: The invention provides a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing one or more substances selected from reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin, and a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin.
Type: Application
Filed: July 22, 2004
Publication date: August 24, 2006
Inventor: Satoru Furukawa, Hideo Kawabe, Hitoshi Ohori, Takao Mukai, Mitsuyo Matsumoto

Receptor Binding Polypeptides
Publication number: 20090022735
Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.
Type: Application
Filed: July 28, 2008
Publication date: January 22, 2009
Applicant: National Health Research Institutes
Inventor: Pele Choi Sing Chong, Shie-Liang Hsieh

RECEPTOR BINDING POLYPEPTIDES
Publication number: 20080213284
Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.
Type: Application
Filed: January 10, 2005
Publication date: September 4, 2008
Inventor: Pele Choi Sing Chong, Shie-Liang Hsieh

PCR primer set for detecting severe acute respiratory syndrome (SARS)-Coronavirus, method and kit for detecting SARS-Coronavirus using the same
Abstract: Provided are SARS-CoV detection PCR primers having nucleotide sequences as set forth in SEQ ID NOS: 1-46, a method for detecting SARS-CoV using the primers, and a SARS-CoV detection kit including the primers.
Type: Grant
Filed: November 24, 2004
Date of Patent: May 20, 2008
Assignee: Samsung Electronics Co., Ltd.
Inventor: Hee-kyun Lim, Sang-hyo Kim, Jung-joo Hwang, Young-sun Lee, Young-a Kim

Protease inhibitors for coronaviruses and SARS-CoV and the use thereof
Abstract: Disclosed are protease inhibitors for coronaviruses and SARS-CoV, or picornaviruses, and the use of these protease inhibitors for preventing, reducing, ameliorating and treating a disease or condition caused by coronaviruses and SARS-CoV, or picornaviruses. Also disclosed are methods of reducing or preventing the spread of coronavirus, or picornaviruses, and preventing or reducing the replication of coronavirus, or picornaviruses, with the compounds of the present invention.
Type: Grant
Filed: May 6, 2004
Date of Patent: March 17, 2009
Assignee: Cytovia, Inc.
Inventor: Sui Xiong Cai, William E. Kemnitzer, Hong Zhang, Han-Zhong Zhang

Interferon for treating or preventing a coronaviral infection
Publication number: 20060280723
Abstract: The present invention provides a composition and method for use in the prevention or treatment of a coronaviral infection and in particular, the human coronavirus infection termed severe acute respiratory syndrome (SARS) coronavirus (SARS-HCoV). A method of treating a coronaviral infection is provided through the administration of interferon, further the use of interferons in the treatment of a coronaviral infection is also provided. Preferred forms of interferon for use in the invention are multi-subtype interferon products such as multi-subtype, human alpha-interferon derived from white blood cells commercially available as Multiferon.
Type: Application
Filed: May 19, 2004
Publication date: December 14, 2006
Applicant: Viragen, Inc
Inventor: Karen Jervis

Receptor binding polypeptides
Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.
Type: Grant
Filed: January 10, 2005
Date of Patent: February 17, 2009
Assignee: National Health Research Institutes
Inventor: Pele Choi Sing Chong, Shie-Liang Hsieh

Materials and methods for the detection of severe acute respiratory syndrome virus (SARS)
Publication number: 20070059686
Abstract: Disclosed are methods and kits for identifying a virus in a sample, which may include a coronavirus capable of causing Severe Acute Respiratory Syndrome (“SARS”) or SARS-like symptoms. The virus may be a SARS-Associated Coronavirus (“SARS-CoV”). Typically, the methods may include reacting a mixture that includes, in addition to nucleic acid isolated from the sample, at least one oligonucleotide capable of specifically hybridizing to SARS-CoV nucleic acid where the oligonucleotide includes at least one non-natural base. In addition, the mixture may include control nucleic acid.
Type: Application
Filed: July 28, 2006
Publication date: March 15, 2007
Inventor: Michael Moser, James Prudent